{"id":70201,"date":"2018-10-17T01:00:00","date_gmt":"2018-12-07T04:41:34","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/12\/07\/963d0c56c2\/"},"modified":"2018-12-07T12:41:47","modified_gmt":"2018-12-07T04:41:47","slug":"963d0c56c2","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/70201\/","title":{"rendered":"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5"},"content":{"rendered":"
\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

2018\u5e749\u6708\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u5171\u6279\u51c62\u4e2a\u65b0\u5206\u5b50\u5b9e\u4f53\uff08NME\uff09\u836f\u7269\uff0c\u5206\u522b\u662f\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684Dacomitinib\uff08\u8fbe\u514b\u66ff\u5c3c\uff09\u4ee5\u53ca\u6cbb\u7597\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\u3001\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u3001\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\u7684Duvelisib\u3002FDA\u8fd8\u9996\u6279\u4e864\u4e2a\u751f\u7269\u5236\u54c1\uff0c\u5206\u522b\u662f\u6cbb\u7597\u8f6c\u79fb\u6027\u76ae\u80a4\u9cde\u72b6\u7ec6\u80de\u764c\u7684Cemiplimab\uff0c\u6cbb\u7597\u504f\u5934\u75db\u7684Galcanezumab\u548cFremanezumab\u4ee5\u53ca\u6cbb\u7597\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\u7684Moxetumomab pasudotox\u3002\u65e5\u672c\u533b\u836f\u54c1\u533b\u7597\u5668\u68b0\u7efc\u5408\u673a\u6784\uff08PMDA\uff09\u5171\u6279\u51c63\u4e2a\u65b0\u5206\u5b50\u5b9e\u4f53\uff08NME\uff09\u836f\u7269\uff0c\u5206\u522b\u4e3a\u6cbb\u7597\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u7684Gilteritinib\u3001\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684Lorlatinib\u4ee5\u53ca\u6cbb\u7597\u9ad8\u773c\u538b\u75c7\u3001\u9752\u5149\u773c\u7684Omidenepag isopropyl\uff0c\u53e6\u5916\u8fd8\u6279\u51c6\u4e86\u4e00\u4e2a\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684\u590d\u65b9Anagliptin\/ Metformin Hydrochloride\u3002\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40NMPA\uff08\u539fCFDA\uff09\u6279\u51c61\u4e2a1\u7c7b\u65b0\u836f\uff0c\u662f\u6cbb\u7597\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u7684\u544b\u55b9\u66ff\u5c3c\uff08Fruquintinib\uff09\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

1<\/span>Cemiplimab<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Cemiplimab\u6700\u521d\u7531\u518d\u751f\u5143\uff08Regeneron\uff09\u5f00\u53d1\uff0c\u4e4b\u540e\u8d5b\u8bfa\u83f2\uff08Sanofi\uff09\u83b7\u5f97\u4e86\u8be5\u836f\u7269\u5728\u7f8e\u56fd\u4ee5\u5916\u5730\u533a\u7684\u7814\u53d1\u548c\u5546\u4e1a\u5316\u6388\u6743\u3002\u4e8e2018\u5e749\u670828\u65e5\u83b7\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aLibtayo\u00ae<\/span><\/sup>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u8f6c\u79fb\u6027\u76ae\u80a4\u9cde\u72b6\u7ec6\u80de\u764c\uff08CSCC\uff09\u6216\u4e0d\u80fd\u63a5\u53d7\u6cbb\u6108\u6027\u624b\u672f\u6216\u653e\u7597\u7684\u5c40\u90e8\u665a\u671fCSCC\u60a3\u8005\u3002\u8fd9\u662fFDA\u6279\u51c6\u7684\u7b2c\u4e00\u4f8b\u9488\u5bf9\u665a\u671fCSCC\u7684\u7597\u6cd5\uff0c\u540c\u65f6\u662f\u7b2c\u4e09\u6b3e\u83b7\u5f97FDA\u6279\u51c6\u7684\u6297PD-1\u6297\u4f53[1]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

CSCC\u662f\u7f8e\u56fd\u7b2c\u4e8c\u5927\u5e38\u89c1\u76ae\u80a4\u764c\u75c7\uff0c\u6700\u5e38\u89c1\u7684\u76ae\u80a4\u764c\u662f\u57fa\u5e95\u7ec6\u80de\u764c\u3002CSCC\u901a\u5e38\u53d1\u751f\u5728\u7ecf\u5e38\u66b4\u9732\u4e8e\u9633\u5149\u6216\u5176\u4ed6\u5f62\u5f0f\u7684\u7d2b\u5916\u7ebf\u8f90\u5c04\u7684\u76ae\u80a4\u533a\u57df\u3002\u867d\u7136\u5927\u591a\u6570CSCC\u60a3\u8005\u901a\u8fc7\u624b\u672f\u5207\u9664\u6cbb\u6108\uff0c\u4f46\u662f\u4e00\u5c0f\u90e8\u5206\u60a3\u8005\u4f1a\u53d1\u5c55\u4e3a\u4e0d\u518d\u5bf9\u5305\u62ec\u624b\u672f\u548c\u653e\u5c04\u5728\u5185\u7684\u5c40\u90e8\u6cbb\u7597\u6709\u53cd\u5e94\u7684\u665a\u671f\u75be\u75c5\u3002\u665a\u671fCSCC\u53ef\u80fd\u5bfc\u81f4\u80bf\u7624\u90e8\u4f4d\u7684\u6bc1\u5bb9\u548c\u5c40\u90e8\u5e76\u53d1\u75c7\u5982\u51fa\u8840\u6216\u611f\u67d3\uff0c\u6216\u8005\u53ef\u80fd\u6269\u6563\uff08\u8f6c\u79fb\uff09\u5230\u5c40\u90e8\u6dcb\u5df4\u7ed3\uff0c\u8fdc\u5904\u7ec4\u7ec7\u548c\u5668\u5b98\u5e76\u53d8\u5f97\u5371\u53ca\u751f\u547d[2]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Libtayo\u00ae<\/span><\/sup>\u7684\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u5f00\u653e\u6807\u7b7e\u7684\u3001\u591a\u4e2d\u5fc3\u7684\u3001\u975e\u968f\u673a\u7684\u4e34\u5e8a\u4e8c\u671f\u8bd5\u9a8c\uff08EMPOWER-CSCC-1 \uff08NCT02760498\uff09\uff09\u4ee5\u53ca\u4e00\u9879\u5f00\u653e\u6807\u7b7e\u7684\uff0c\u975e\u968f\u673a\u7684\u4e34\u5e8a\u4e00\u671f\u6269\u5c55\u961f\u5217\u8bd5\u9a8c\uff08NCT02383212\uff09\u3002\u5171\u6709108\u540d\u60a3\u8005\uff0875\u540d\u60a3\u6709\u8f6c\u79fb\u6027\u75be\u75c5\uff0c33\u540d\u60a3\u6709\u5c40\u90e8\u665a\u671f\u75be\u75c5\uff09\u88ab\u7eb3\u5165\u7597\u6548\u8bc4\u4f30\u3002\u8be5\u7814\u7a76\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u5ba2\u89c2\u53cd\u5e94\u7387\uff0c\u6216\u6cbb\u7597\u540e\u80bf\u7624\u90e8\u5206\u7f29\u5c0f\u6216\u5b8c\u5168\u6d88\u5931\u7684\u60a3\u8005\u767e\u5206\u6bd4\u3002\u7ed3\u679c\u663e\u793a\uff0c\u4f7f\u7528Libtayo\u00ae<\/span><\/sup>\u6cbb\u7597\u7684\u6240\u6709\u60a3\u8005\u4e2d\u670947\uff05\u7684\u60a3\u8005\u80bf\u7624\u7f29\u5c0f\u6216\u6d88\u5931\u3002\u8fd9\u4e9b\u60a3\u8005\u4e2d\u7684\u5927\u591a\u6570\u5728\u6570\u636e\u5206\u6790\u65f6\u5177\u6709\u6301\u7eed\u7684\u53cd\u5e94[3]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

Libtayo\u00ae<\/span><\/sup>\u662f\u4e00\u79cd\u9488\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u53d7\u4f53PD-1\uff08\u7a0b\u5e8f\u6027\u7ec6\u80de\u6b7b\u4ea1\u86cb\u767d-1\uff09\u7684\u5168\u4eba\u6e90\u5355\u514b\u9686\u6297\u4f53\uff0c\u901a\u8fc7\u963b\u65adPD-1\u4fe1\u53f7\u901a\u8def\uff0c\u5b83\u53ef\u4ee5\u5e2e\u52a9\u4eba\u4f53\u7684\u514d\u75ab\u7cfb\u7edf\u6740\u4f24\u80bf\u7624\u7ec6\u80de\u3002\u5b83\u662f\u7b2c\u4e00\u4e2a\u4e5f\u662f\u552f\u4e00\u4e00\u4e2a\u4e13\u95e8\u6279\u51c6\u5e76\u53ef\u7528\u4e8e\u665a\u671fCSCC\u7684\u6cbb\u7597\u836f\u7269\u3002\u8fd9\u6b3e\u836f\u7269\u53ef\u7528\u4e8e\u5e2e\u52a9\u90a3\u4e9b\u7ecf\u8fc7\u5916\u79d1\u624b\u672f\u548c\u5316\u5b66\u7597\u6cd5\u6cbb\u7597\u4ecd\u672a\u89c1\u597d\u8f6c\u7684\u76ae\u80a4\u764c\u60a3\u8005\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

2<\/span>Galcanezumab<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Galcanezumab\u7531\u793c\u6765\u516c\u53f8\u7814\u53d1\uff0c\u4e8e2018\u5e749\u670827\u65e5\u83b7\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aEmgality\u00ae<\/span><\/sup>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u6210\u4eba\u60a3\u8005\u504f\u5934\u75db[4]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u504f\u5934\u75db\u662f\u4e34\u5e8a\u4e0a\u5e38\u89c1\u7684\u5934\u75db\u7c7b\u578b\u4e4b\u4e00\uff0c\u4ee5\u53cd\u590d\u53d1\u4f5c\u6027\u7684\u5934\u75db\u4e3a\u7279\u70b9\uff0c\u53d1\u4f5c\u95f4\u6b47\u671f\u6b63\u5e38\u3002\u901a\u5e38\u4f34\u6709\u5404\u79cd\u81ea\u4e3b\u795e\u7ecf\u7cfb\u7edf\u75c7\u72b6\u3002\u504f\u5934\u75db\u7684\u75c5\u56e0\u88ab\u8ba4\u4e3a\u662f\u73af\u5883\u56e0\u7d20\u548c\u9057\u4f20\u56e0\u7d20\u7684\u7efc\u5408\u4f5c\u7528\u6240\u81f4\u3002\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u5c06\u5176\u5217\u4e3a\u6700\u81f4\u4eba\u8870\u5f31\u7684\u75be\u75c5\u4e4b\u4e00\u3002\u7531\u4e8e\u8377\u5c14\u8499\u7684\u5f71\u54cd\uff0c\u504f\u5934\u75db\u591a\u89c1\u4e8e\u5973\u6027\uff0c\u7537\u5973\u60a3\u8005\u7684\u6bd4\u4f8b\u901a\u5e38\u4e3a1\uff1a2\u3002\u9996\u6b21\u53d1\u75c5\u5e38\u4e8e10-30\u5c81\u4e4b\u95f4\uff0c\u53d7\u5230\u5f71\u54cd\u7684\u5927\u591a\u6570\u4eba\u5e74\u9f84\u572835\u5c81\u548c45\u5c81\u4e4b\u95f4\u3002\u8fd1\u5e74\u6765\uff0c\u79d1\u5b66\u5bb6\u5bf9\u504f\u5934\u75db\u7684\u673a\u5236\u6709\u4e86\u8fdb\u4e00\u6b65\u4e86\u89e3\uff0c\u4f46\u5bf9\u5177\u4f53\u4fe1\u53f7\u901a\u8def\u548c\u751f\u7269\u6807\u8bb0\u7269\u7684\u8ba4\u8bc6\u5c1a\u4e0d\u5145\u5206\u3002\u964d\u9499\u7d20\u57fa\u56e0\u76f8\u5173\u80bd\uff08calcitonin gene-related peptide\uff0cCGRP\uff09\u901a\u8def\u662f\u7b2c\u4e00\u4e2a\u88ab\u7814\u7a76\u7684\u836f\u7269\u9776\u70b9\u3002CGRP\u53ca\u5176\u53d7\u4f53\u5728\u4e0e\u504f\u5934\u75db\u75c5\u7406\u751f\u7406\u5b66\u76f8\u5173\u7684\u795e\u7ecf\u7cfb\u7edf\u533a\u57df\u8868\u8fbe\u3002\u5230\u76ee\u524d\u4e3a\u6b62\u7814\u7a76\u8868\u660e\u963b\u65adCGRP\u901a\u8def\u5bf9\u4e8e\u6cbb\u7597\u504f\u5934\u75db\u662f\u6709\u6548\u7684\u3002\u5b83\u4e0e\u73b0\u6709\u7684\u66f2\u5766\u7c7b\uff08\u8840\u6e05\u7d201B\/1D\u6fc0\u52a8\u5242\uff09\u548c\u963f\u7247\u7c7b\u836f\u7269\u7684\u4f5c\u7528\u673a\u5236\u660e\u663e\u4e0d\u540c[5]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Emgality\u00ae<\/span><\/sup>\u662f\u4e00\u79cd\u4eba\u6e90\u5316\u5355\u514b\u9686\u6297\u4f53\uff0c\u9776\u5411\u4e8e\u964d\u9499\u7d20\u57fa\u56e0\u76f8\u5173\u80bd\uff08CGRP\uff09\uff0c\u8be5\u53d7\u4f53\u5728\u504f\u5934\u75db\u7684\u53d1\u751f\u4e2d\u53d1\u6325\u4e86\u5173\u952e\u4f5c\u7528\u3002CGRP\u662f\u4e00\u79cd\u795e\u7ecf\u80bd\uff0c\u5df2\u88ab\u8bc1\u660e\u5728\u504f\u5934\u75db\u53d1\u4f5c\u65f6\u91ca\u653e\uff0c\u88ab\u8ba4\u4e3a\u662f\u504f\u5934\u75db\u53d1\u4f5c\u7684\u8bf1\u56e0\u3002\u76ee\u524d\uff0cCGRP\u53d7\u4f53\u5df2\u6210\u4e3a\u504f\u5934\u75db\u836f\u7269\u7814\u53d1\u7684\u70ed\u95e8\u9776\u70b9\u3002<\/span><\/p>\n


<\/span><\/p>\n

Emgality\u00ae<\/span><\/sup>\u7684\u83b7\u6279\uff0c\u662f\u57fa\u4e8e\u5728\u53d1\u4f5c\u6027\u504f\u5934\u75db\uff08EM\uff09\u60a3\u8005\u4e2d\u5f00\u5c55\u76842\u9879\u4e09\u671f\u4e34\u5e8a\u7814\u7a76\uff08EVOLVE-1\uff0cEVOLVE-2\uff09\u4ee5\u53ca\u5728\u6162\u6027\u504f\u5934\u75db\uff08CM\uff09\u60a3\u8005\u4e2d\u5f00\u5c55\u7684\u4e00\u9879\u4e09\u671f\u4e34\u5e8a\u7814\u7a76\uff08REGAIN\uff09\u7684\u6570\u636e\u3002\u5728\u4e09\u9879\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u968f\u673a\u63a5\u53d7\u6bcf\u6708\u4e00\u6b21\u7684\u5b89\u6170\u5242\uff0c\u521d\u59cb\u8d1f\u8377\u5242\u91cf\u4e3a240 mg\u540e\u7684Emgality 120 mg\u6216Emgality 240 mg\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u610f\u5411\u6cbb\u7597\u7814\u7a76\u4eba\u7fa4\u4e2d\u53cc\u76f2\u6cbb\u7597\u671f\u95f4\u6bcf\u6708MHD\u6570\u91cf\u4e0e\u57fa\u7ebf\u7684\u5e73\u5747\u53d8\u5316\u3002\u6570\u636e\u663e\u793a\uff0c\u4e0e\u5b89\u6170\u5242\u76f8\u6bd4\uff0cEmgality\u6a2a\u8de8\u504f\u5934\u75db\u8c31\u5728\u51cf\u5c11\u6bcf\u6708\u504f\u5934\u75db\u5929\u6570\u65b9\u9762\u8868\u73b0\u51fa\u4e34\u5e8a\u610f\u4e49\u548c\u7edf\u8ba1\u5b66\u610f\u4e49\u7684\u663e\u8457\u7597\u6548[6]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u6b64\u6b21\u6279\u51c6\uff0c\u4f7fEmgality\u00ae<\/span><\/sup>\u6210\u4e3a\u7ee7\u8bfa\u534e\/\u5b89\u8fdbAimovig\u00ae <\/span><\/sup>\uff08erenumab-aooe\uff09\u548c\u68af\u74e6Ajovy\u00ae <\/span><\/sup>\uff08fremanezumab-vfrm\uff09\u4e4b\u540e\u4e0a\u5e02\u7684\u7b2c3\u6b3e\u9776\u5411CGRP\u7684\u504f\u5934\u75db\u836f\u7269\u3002\u7528\u836f\u65b9\u9762\uff0cAimovig\u548cEmgality\u5747\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\uff0cAjovy\u6bcf\u6708\u4e00\u6b21\u6216\u6bcf3\u4e2a\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\uff0c\u5c06\u4e3a\u60a3\u8005\u63d0\u4f9b\u4e00\u79cd\u5dee\u5f02\u5316\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

3<\/span>Dacomitinib(\u8fbe\u514b\u66ff\u5c3c)<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Dacomitinib\u6700\u521d\u7531\u8f89\u745e\u7814\u53d1\uff0c2012\u5e74\u6388\u6743\u7ed9SFJ Pharmaceuticals\u5408\u4f5c\u5f00\u53d1\u3002\u4e8e2018\u5e749\u670827\u65e5\u83b7\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aVizimpro\u00ae<\/span><\/sup>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u643a\u5e26EGFR\u57fa\u56e0\u5916\u663e\u5b5019\u7f3a\u5931\u6216\u5916\u663e\u5b5021 L858R\u7f6e\u6362\u7a81\u53d8\u7684\u8f6c\u79fb\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005[7]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u80ba\u764c\u662f\u4e16\u754c\u4e0a\u6700\u5e38\u89c1\u7684\u6076\u6027\u80bf\u7624\u4e4b\u4e00\uff0c\u5df2\u6210\u4e3a\u6211\u56fd\u57ce\u5e02\u4eba\u53e3\u6076\u6027\u80bf\u7624\u6b7b\u4ea1\u539f\u56e0\u7684\u7b2c\u4e00\u4f4d\uff0c\u5e76\u4e14\u4e5f\u662f2008\u5e74\u5168\u7403\u8303\u56f4\u5185\u7537\u6027\u764c\u75c7\u6b7b\u4ea1\u7684\u4e00\u4e2a\u4e3b\u8981\u539f\u56e0\u3002\u5728\u5973\u6027\u5f53\u4e2d\uff0c\u5b83\u662f\u7b2c\u56db\u5927\u6700\u5e38\u89c1\u88ab\u8bca\u65ad\u51fa\u7684\u764c\u75c7\u548c\u764c\u75c7\u6b7b\u4ea1\u7684\u7b2c\u4e8c\u4e3b\u8981\u539f\u56e0\u3002\u975e\u5c0f\u7ec6\u80de\u578b\u80ba\u764c\uff08Non-Small Lung Cancer\uff0cNSCLC\uff09\u662f\u80ba\u764c\u6700\u5e38\u89c1\u7684\u7ec4\u7ec7\u5b66\u7c7b\u578b[8]<\/span><\/sup>\uff0c\u662f\u9664\u5c0f\u7ec6\u80de\u80ba\u764c\uff08SCLC\uff09\u4e4b\u5916\u7684\u5176\u4f59\u4e0a\u76ae\u6027\u80ba\u764c\u3002\u6700\u5e38\u89c1\u7684NSCLC\u4e3a\u9cde\u72b6\u7ec6\u80de\u764c\u3001\u5927\u7ec6\u80de\u764c\u548c\u817a\u764c\uff0c\u4f46\u4e5f\u6709\u5176\u4ed6\u53d1\u75c5\u7387\u8f83\u4f4e\u7684\u7c7b\u578b\uff0c\u6240\u6709\u7c7b\u578b\u90fd\u53ef\u4ee5\u53d1\u751f\u5c11\u89c1\u7684\u79cd\u7ec4\u7ec7\u5b66\u53d8\u5f02[9]<\/span><\/sup>\u3002\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ea6\u5360\u6240\u6709\u80ba\u764c\u768475%\uff0c\u8d85\u8fc7\u4e09\u5206\u4e4b\u4e8c\u7684\u60a3\u8005\u53d1\u73b0\u65f6\u5df2\u5904\u4e8e\u4e2d\u665a\u671f\uff0c5\u5e74\u751f\u5b58\u7387\u5f88\u4f4e\u3002EGFR\u662f\u4e00\u79cd\u5e2e\u52a9\u7ec6\u80de\u751f\u957f\u548c\u5206\u88c2\u7684\u86cb\u767d\u8d28\u3002\u5f53EGFR\u57fa\u56e0\u7a81\u53d8\u65f6\uff0c\u5b83\u53ef\u80fd\u5bfc\u81f4\u86cb\u767d\u8d28\u8fc7\u5ea6\u6d3b\u8dc3\uff0c\u5bfc\u81f4\u764c\u7ec6\u80de\u5f62\u6210\u3002EGFR\u7a81\u53d8\u53ef\u80fd\u5728\u5168\u740310\uff05\u81f335\uff05\u7684NSCLC\u80bf\u7624\u4e2d\u53d1\u751f\uff0c\u5e76\u4e14\u6700\u5e38\u89c1\u7684\u6fc0\u6d3b\u7a81\u53d8\u662f\u5916\u663e\u5b5019\u548c\u5916\u663e\u5b5021 L858R\u53d6\u4ee3\u4e2d\u7684\u7f3a\u5931\uff0c\u5176\u5171\u540c\u5360\u5df2\u77e5\u6fc0\u6d3bEGFR\u7a81\u53d8\u768480\uff05\u4ee5\u4e0a\u3002\u8be5\u75be\u75c5\u4e0e\u4f4e\u5b58\u6d3b\u7387\u76f8\u5173\uff0c\u75be\u75c5\u8fdb\u5c55\u4ecd\u7136\u662f\u4e00\u4e2a\u6311\u6218[10,11]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Vizimpro\u00ae<\/span><\/sup>\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u540d\u4e3aARCHER 1050\u7684\u968f\u673a\u7684\u3001\u591a\u4e2d\u5fc3\u7684\u3001\u56fd\u9645\u6027\u7684\u3001\u5f00\u653e\u6807\u7b7e\u7684\u4e34\u5e8a\u4e09\u671f\u8bd5\u9a8c\u7684\u7ed3\u679c\u3002\u603b\u8ba1452\u540d\u60a3\u8005\u88ab\u968f\u673a\u5206\u4e3a\u4e24\u7ec4\uff0c\u63a5\u53d7Vizimpro\u6216\u8005\u6d3b\u6027\u5bf9\u7167\u7684\u6cbb\u7597\u3002\u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u4e3a\u7531\u72ec\u7acb\u7684\u653e\u5c04\u5b66\u5ba1\u67e5\u59d4\u5458\u4f1a\uff08IRC\uff09\u8bc4\u4f30\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u3002\u6839\u636eIRC\u8bc4\u4f30\u7684PFS\uff0cVizimpro\u4e0e\u6d3b\u6027\u5bf9\u7167\u76f8\u6bd4\uff0c\u663e\u8457\u5ef6\u957f\u4e86\u60a3\u8005\u7684\u4e2d\u4f4dPFS\uff08p<0.0001\uff09\u3002Vizimpro\u6cbb\u7597\u7ec4PFS\u4e3a14.7\u4e2a\u6708\uff0895% CI: 11.1, 16.6\uff09\uff0c\u6d3b\u6027\u5bf9\u7167\u7ec4\u4e3a9.2\u4e2a\u6708\uff0895% CI: 9.1, 11.0\uff09[12]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

EGFR\u7a81\u53d8\u7684\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u662f\u4e00\u79cd\u5e38\u89c1\u75be\u75c5\uff0c\u7279\u522b\u662f\u5728\u4e9a\u6d32\u4eba\u7fa4\u4e2d\uff0cVizimpro\u00ae<\/span><\/sup>\u7684\u4e0a\u5e02\u4e3a\u6cbb\u6108\u72ec\u7279\u6027\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u63d0\u4f9b\u4e86\u66f4\u591a\u7684\u9009\u62e9\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

4<\/span>Duvelisib<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

Duvelisib\u4e8e2018\u5e749\u670824\u65e5\u83b7\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u7531Verastem\u4e0a\u5e02\u9500\u552e\uff0c\u5546\u54c1\u540d\u4e3aCopiktra\u00ae<\/span><\/sup>\u3002Duvelisib\u6700\u521d\u662f\u7531Intellikine\uff08\u540e\u88ab\u6b66\u7530\u6536\u8d2d\uff09\u7814\u53d1\uff0c\u540eInfinity\u83b7\u5f97\u4e86\u8be5\u5316\u5408\u7269\u5168\u7403\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6743\u5229\u30022014\u5e74\uff0cInfinity\u4e0e\u827e\u4f2f\u7ef4\u8fbe\u6210\u5408\u4f5c\u534f\u8bae\u8054\u5408\u5f00\u53d1Duveraisib\uff0c\u7136\u800c2016\u5e74\u827e\u4f2f\u7ef4\u7ec8\u6b62\u4e86\u4e0eInfinity\u7684\u5408\u4f5c\uff0cInfinity\u91cd\u65b0\u83b7\u5f97\u4e86duvelisib\u7684\u5168\u7403\u6743\u5229\u30022016\u5e7411\u6708\uff0cInfinity\u6388\u6743\u7ed9Verastem\uff08\u73b0\u4e3aVerastem Oncology\uff09\u5f00\u53d1\u548c\u5546\u4e1a\u5316duvelisib\u7684\u5168\u7403\u72ec\u5bb6\u6743\u5229\u3002Copiktra\u00ae<\/span><\/sup>\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u81f3\u5c11\u4e24\u6b21\u65e2\u5f80\u6cbb\u7597\u540e\u590d\u53d1\u6216\u96be\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08CLL\uff09\u6216\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08SLL\uff09\u548c\u81f3\u5c11\u4e24\u6b21\u65e2\u5f80\u6cbb\u7597\u540e\u590d\u53d1\u6216\u96be\u6cbb\u6027\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\uff08FL\uff09[13]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

CLL\/SLL\u662f\u4e3b\u8981\u53d1\u751f\u5728\u4e2d\u8001\u5e74\u4eba\u7fa4\u7684\u4e00\u79cd\u6210\u719fB\u6dcb\u5df4\u7ec6\u80de\u514b\u9686\u589e\u6b96\u6027\u80bf\u7624\uff0c\u4ee5\u6dcb\u5df4\u7ec6\u80de\u5728\u5916\u5468\u8840\u3001\u9aa8\u9ad3\u3001\u813e\u810f\u548c\u6dcb\u5df4\u7ed3\u805a\u96c6\u4e3a\u7279\u5f81\u3002SLL\u4e0eCLL\u662f\u540c\u4e00\u79cd\u75be\u75c5\u7684\u4e0d\u540c\u8868\u73b0\u3002\u8fd9\u4e24\u79cd\u75be\u75c5\u4e4b\u95f4\u7684\u552f\u4e00\u533a\u522b\u662f\uff1a\u5728CLL\u4e2d\uff0c\u7ec6\u80de\u4e3b\u8981\u5b58\u5728\u4e8e\u8840\u6db2\u548c\u9aa8\u9ad3\u4e2d\uff1b\u800c\u5728SLL\u4e2d\uff0c\u7ec6\u80de\u4e3b\u8981\u5b58\u5728\u4e8e\u6dcb\u5df4\u7ed3\u4e2d[14]<\/span><\/sup>\u3002CLL\/SLL\u7684\u75c7\u72b6\u5305\u62ec\u8179\u90e8\u80bf\u80c0\uff0c\u5373\u4f7f\u4ec5\u5c11\u91cf\u8fdb\u98df\u4e5f\u611f\u89c9\u9971\u8179\u3002\u5176\u4ed6\u75c7\u72b6\u5305\u62ec\u75b2\u52b3\uff0c\u547c\u5438\u77ed\u4fc3\uff0c\u8d2b\u8840\uff0c\u5bb9\u6613\u7600\u4f24\uff0c\u76d7\u6c57\uff0c\u4f53\u91cd\u51cf\u8f7b\u548c\u9891\u7e41\u611f\u67d3\u3002\u7136\u800c\uff0c\u8bb8\u591aCLL\/SLL\u60a3\u8005\u4f1a\u5b58\u6d3b\u591a\u5e74\u800c\u6ca1\u6709\u75c7\u72b6\u3002\u867d\u7136\u76ee\u524d\u6709\u6cbb\u7597\u65b9\u6cd5\uff0c\u4f46\u5927\u91cf\u60a3\u8005\u5728\u6cbb\u7597\u540e\u590d\u53d1\uff0c\u5bf9\u5f53\u524d\u836f\u7269\u96be\u4ee5\u6cbb\u7597\uff0c\u6216\u8005\u65e0\u6cd5\u8010\u53d7\u6cbb\u7597\uff0c\u8fd9\u4ee3\u8868\u4e86\u91cd\u8981\u7684\u533b\u7597\u9700\u6c42\u3002\u989d\u5916\u53e3\u670d\u836f\u7269\u7684\u6f5c\u529b\uff0c\u7279\u522b\u662f\u4f5c\u4e3a\u53ef\u7528\u4e8e\u4e00\u822c\u793e\u533a\u533b\u751f\u7684\u6b66\u5668\u88c5\u5907\u7684\u5355\u4e00\u7597\u6cd5\uff0c\u53ef\u80fd\u5bf9CLL\/SLL\u60a3\u8005\u7684\u6cbb\u7597\u5177\u6709\u91cd\u8981\u4ef7\u503c[15]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\uff08follicular lymphoma\uff0cFL\uff09\u662f\u6700\u5e38\u89c1\u7684\u60f0\u6027\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08non-Hodgkin’s lymphoma\uff0cNHL\uff09\uff0c\u5176\u53d1\u75c5\u7387\u9010\u5e74\u589e\u9ad8\uff0c\u5176\u9057\u4f20\u6807\u8bb0\u662ft (14;18)  (q32;q21)\u5f02\u4f4d\uff0c\u5bfc\u81f4BCL2\u86cb\u767d\u6301\u7eed\u8fc7\u91cf\u8868\u8fbe\uff0c\u635f\u5bb3\u4e86\u6b63\u5e38\u751f\u53d1\u4e2d\u5fc3\u7684\u51cb\u4ea1\u529f\u80fd\u3002\u7ec4\u7ec7\u5b66\u7279\u5f81\u662f\u4f4e\u500d\u955c\u4e0b\u80bf\u7624\u7ec6\u80de\u5448\u73b0\u660e\u663e\u7684\u7ed3\u8282\u72b6\u751f\u957f\u3002\u80bf\u7624\u6027\u6ee4\u6ce1\u4e3b\u8981\u7531\u4e0d\u540c\u6bd4\u4f8b\u7684\u4e2d\u5fc3\u7ec6\u80de\u548c\u4e2d\u5fc3\u6bcd\u7ec6\u80de\u7ec4\u6210\uff0c\u4e2d\u5fc3\u7ec6\u80de\u7684\u6838\u6709\u88c2\u6c9f\uff0c\u79f0\u4e3a\u5c0f\u6838\u88c2\u7ec6\u80de\uff1b\u4e2d\u5fc3\u6bcd\u7ec6\u80de\u4f53\u79ef\u5927\uff0c\u6838\u5706\u5f62\u6216\u5206\u53f6\u72b6\uff0c\u79f0\u4e3a\u65e0\u6838\u88c2\u7ec6\u80de\u3002FL\u6700\u5e38\u89c1\u4e34\u5e8a\u8868\u73b0\u662f\u65e0\u75db\u6027\u6dcb\u5df4\u7ed3\u80bf\u5927\uff0c\u5178\u578b\u4e34\u5e8a\u8868\u73b0\u4e3a\u591a\u90e8\u4f4d\u6dcb\u5df4\u7ec4\u7ec7\u4fb5\u72af\u3002FL\u662f\u5bf9\u5316\u7597\u548c\u653e\u7597\u6700\u654f\u611f\u7684\u6076\u6027\u80bf\u7624\u4e4b\u4e00\uff0c\u5728\u65e9\u671f\u9636\u6bb5\uff0c\u4e3b\u8981\u4e3a\u653e\u7597\uff0c\u5728\u75be\u75c5\u8fdb\u5c55\u81f3\u665a\u671f\u65f6\uff0c\u8fdb\u884c\u5316\u7597\u6216\u4f7f\u7528\u514d\u75ab\u6cbb\u7597[16]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Duvelisib\u662fPI3K\u7684\u6291\u5236\u5242\uff0c\u5176\u6291\u5236\u6d3b\u6027\u4e3b\u8981\u9488\u5bf9PI3K\u03b4\u548cPI3K\u03b3\u4e9a\u578b\u3002Duvelisib\u53ef\u4ee5\u6291\u5236\u6076\u6027B\u7ec6\u80de\u548c\u539f\u53d1\u6027CLL\u80bf\u7624\u7ec6\u80de\u7684\u751f\u957f\u5e76\u964d\u4f4e\u5b83\u4eec\u7684\u5b58\u6d3b\u7387\u3002\u5b83\u8fd8\u80fd\u6291\u5236\u591a\u79cd\u5173\u952e\u7ec6\u80de\u4fe1\u53f7\u901a\u8def\uff0c\u5305\u62ecB\u7ec6\u80de\u53d7\u4f53\u4fe1\u53f7\u8f6c\u5bfc\u548cCXCR12\u4ecb\u5bfc\u7684\u6076\u6027B\u7ec6\u80de\u8d8b\u5316\u4f5c\u7528\u3002\u6b64\u5916\uff0cDuvelisib\u8fd8\u53ef\u4ee5\u6291\u5236CXCL12\u8bf1\u5bfc\u7684T\u7ec6\u80de\u8fc1\u79fb\u548c\u5de8\u566c\u7ec6\u80de\u7684M- CSF\u548cIL-4\u9a71\u52a8\u7684M2\u6781\u5316[17]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

Copiktra\u00ae<\/span><\/sup>\u83b7\u6279\u6cbb\u7597CLL\/SLL\u662f\u57fa\u4e8e\u4e00\u9879\u968f\u673a\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6807\u7b7e\u7684\u4e34\u5e8a\u4e09\u671f\u8bd5\u9a8c\uff08NCT02004522\uff09\uff0c\u6bd4\u8f83Copiktra\u00ae<\/span><\/sup>\u4e0eofatumumab\u6cbb\u7597\u590d\u53d1\u6216\u96be\u6cbb\u6027CLL\u6216SLL\u7684\u60a3\u8005\u3002\u8be5\u8bd5\u9a8c\u7eb3\u5165\u81f3\u5c11\u7ecf\u8fc7\u4e00\u6b21\u6cbb\u7597\u7684\u60a3\u6709CLL\uff08N = 312\uff09\u6216SLL\uff08N = 7\uff09\u7684\u5171\u8ba1319\u540d\u6210\u4eba\u60a3\u8005\uff0c\u8be5\u7814\u7a76\u5c06\u60a3\u8005\u6309\uff081\uff1a1\uff09\u968f\u673a\u5206\u4e3a\u6bcf\u65e5\u4e24\u6b21\u53e3\u670d25mg Copiktra\u00ae<\/span><\/sup>\u76f4\u81f3\u75be\u75c5\u597d\u8f6c\u6216\u4e0d\u53ef\u63a5\u53d7\u7684\u6bd2\u6027\u6216\u8005\u63a5\u53d7Ofatumumab\u9759\u8109\u7ed9\u836f7\u4e2a\u5468\u671f\u3002\u800c\u63a5\u53d7\u8fc7\u81f3\u5c112\u6b21\u6cbb\u7597\u7684196\u540d\u60a3\u8005\uff0c\u5176\u4e2d95\u540d\u968f\u673a\u63a5\u53d7Copiktra\u00ae<\/span><\/sup>\u6cbb\u7597\uff0c101\u540d\u63a5\u53d7ofatumumab\u6cbb\u7597\uff0c\u7531\u72ec\u7acb\u8bc4\u5ba1\u59d4\u5458\u4f1a\uff08IRC\uff09\u8bc4\u4f30\u7684\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u5728Copiktra\u00ae<\/span><\/sup>\u7ec4\u4e3a16.4\u4e2a\u6708\uff0cofatumumab\u7ec4\u4e3a9.1\u4e2a\u6708\uff08\u98ce\u9669\u6bd4\u4e3a0.40;\u6807\u51c6\u8bef\u5dee\u4e3a0.2\uff09\u3002\u51e0\u4e4e\u662fofatumumab\u76842\u500d\uff0c\u5bf9\u4e8eCopiktra\u00ae<\/span><\/sup>\u548cofatumumab\u7ec4\uff0c\u6bcf\u4e2aIRC\u7684\u603b\u53cd\u5e94\u7387\uff08ORR\uff09\u5206\u522b\u4e3a78\uff05\u548c39\uff05\uff08\u5dee\u5f02\u4e3a39\uff05\uff0c\u6807\u51c6\u8bef\u5dee\u4e3a6.5\uff05\uff09\u3002Copiktra\u00ae<\/span><\/sup>\u6cbb\u7597\u7ec4\u7684\u4e3b\u8981\u548c\u6b21\u8981\u7ec8\u70b9\u5747\u5f97\u5230\u663e\u8457\u6539\u5584\u3002<\/span><\/p>\n


<\/span><\/p>\n

Copiktra\u00ae<\/span><\/sup>\u83b7\u6279\u6cbb\u7597FL\u662f\u57fa\u4e8e\u4e00\u9879\u5355\u81c2\u591a\u4e2d\u5fc3\u8bd5\u9a8c\uff08NCT02204982\uff09\uff0c\u8be5\u8bd5\u9a8c\u7eb3\u5165\u4e8683\u4f8bFL\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u4f7f\u7528\u5229\u59a5\u6614\u5355\u6297\u96be\u4ee5\u6cbb\u7597\uff0c\u65e0\u8bba\u662f\u5316\u7597\u8fd8\u662f\u653e\u5c04\u514d\u75ab\u6cbb\u7597\u3002\u7531IRC\u786e\u5b9a\u7684ORR\u4e3a42\uff05\uff0895\uff05CI\uff1a31, 54\uff09\uff0c41\uff05\u7684\u60a3\u8005\u7ecf\u5386\u90e8\u5206\u53cd\u5e94\uff0c1\u540d\u60a3\u8005\u5177\u6709\u5b8c\u5168\u53cd\u5e94\u3002\u572835\u540d\u54cd\u5e94\u60a3\u8005\u4e2d\uff0c15\u540d\uff0843\uff05\uff09\u7ef4\u6301\u81f3\u5c116\u4e2a\u6708\u7684\u53cd\u5e94\uff0c6\u540d\uff0817\uff05\uff09\u7ef4\u6301\u81f3\u5c1112\u4e2a\u6708\u7684\u53cd\u5e94\u3002Copiktra\u00ae<\/span><\/sup>\u7ec4\u76f8\u6bd4\u5229\u59a5\u6614\u5355\u6297\u7ec4\u5bf9FL\u60a3\u8005\u7684\u6cbb\u7597\u5f97\u5230\u4e86\u663e\u8457\u6539\u5584[18]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

Copiktra\u00ae<\/span><\/sup>\u662f\u7b2c\u4e00\u4e2a\u88abFDA\u6279\u51c6\u7684PI3K\u03b4\u548cPI3K\u03b3\u7684\u53cc\u91cd\u6291\u5236\u5242\uff0c\u662fCLL\/SLL\u548cFL\u60a3\u8005\u4e0d\u65ad\u53d1\u5c55\u7684\u6cbb\u7597\u8303\u5f0f\u7684\u91cd\u8981\u8865\u5145\uff0cCopiktra\u00ae<\/span><\/sup>\u662f\u533b\u751f\u6cbb\u7597\u8bbe\u5907\u7684\u4e00\u4e2a\u91cd\u8981\u8865\u5145\u3002\u6b64\u5916\uff0c\u5728\u7f8e\u56fd\u548c\u6b27\u76df\uff0cduvelisib\u5747\u88ab\u6388\u4e88\u6cbb\u7597CLL\u3001SLL\u3001FL\u7684\u5b64\u513f\u836f\u5730\u4f4d\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

5<\/span>Fremanezumab<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Fremanezumab\u4e8e2018\u5e749\u670814\u65e5\u83b7\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u6700\u521d\u7531Rinat Neuroscience\uff082006\u5e74\u88ab\u8f89\u745e\u6536\u8d2d\uff09\u5f00\u53d1\uff0c2013\u5e74Labrys Biologics\uff082014\u5e74\u88ab\u68af\u74e6\u6536\u8d2d\uff09\u83b7\u5f97\u8be5\u836f\u7684\u5168\u7403\u7814\u53d1\u6743\u3002\u5546\u54c1\u540d\u4e3aAjovy\u00ae<\/span><\/sup>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u6210\u4eba\u504f\u5934\u75db[19]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u964d\u9499\u7d20\u57fa\u56e0\u76f8\u5173\u80bd\uff08CGRP\uff09\u662f\u4e00\u4e2a\u542b\u670937\u4e2a\u6c28\u57fa\u9178\u6b8b\u57fa\u7684\u9178\u6027\u795e\u7ecf\u80bd\uff0c\u662f\u76ee\u524d\u6700\u4e3a\u5f3a\u5927\u7684\u5185\u6e90\u6027\u8840\u7ba1\u8212\u5f20\u7269\u8d28\u3002CGRP \u5177\u6709\u4e24\u79cd\u4e3b\u8981\u4e9a\u578b\uff08\u03b1\u548c\u03b2\uff09\uff0c\u5b83\u4eec\u6709\u76f8\u4f3c\u7684\u7ed3\u6784\u548c\u751f\u7269\u6d3b\u6027\uff0c\u4e14\u7531\u5355\u72ec\u7684\u57fa\u56e0\u5408\u6210\u3002CGRP \u51e0\u4e4e\u5b58\u5728\u4e8e\u6240\u6709\u7684\u611f\u89c9\u795e\u7ecf\u7ea4\u7ef4\u5185\uff0c\u4e14\u5206\u5e03\u4e0e\u8840\u7ba1\u7d27\u5bc6\u76f8\u8fde\uff0c\u03b1-CGRP\u4e3b\u8981\u5b58\u5728\u4e8e\u4e2d\u67a2\u548c\u5468\u56f4\u611f\u89c9\u795e\u7ecf\u7cfb\u7edf\u4e2d\uff0c\u5176\u4e2d\u4e09\u53c9\u795e\u7ecf\u8282\u548c\u80cc\u6839\u795e\u7ecf\u8282\u662f\u5176\u5408\u6210\u53ca\u91ca\u653e\u7684\u4e3b\u8981\u573a\u6240\u3002\u03b2-CGRP\u4e3b\u8981\u5b58\u5728\u4e8e\u80a0\u9053\u795e\u7ecf\u7cfb\u7edf\u3002<\/span>CGRP\u7ed3\u5408\u4e8e\u7279\u5f02\u6027\u7684CGRP\u53d7\u4f53\u53d1\u6325\u751f\u7269\u5b66\u6d3b\u6027\uff0c\u5176\u53d7\u4f53\u75317\u4e2a\u8de8\u819c\u86cb\u767d\u590d\u5408\u4f53\uff08\u964d\u9499\u7d20\u53d7\u4f53\u6837\u53d7\u4f53\uff08calcitonin receptor-likereceptor\uff0cCLR\uff09\uff0c1\u4e2a\u8de8\u819c\u86cb\u767d\u53d7\u4f53\u6d3b\u6027\u4fee\u9970\u86cb\u767d\uff08receptor activity modifying protein 1\uff0cRAMP-1\uff09\u548c1\u4e2a\u80de\u5185\u86cb\u767d-\u53d7\u4f53\u5408\u6210\u86cb\u767d\uff08receptor component protein\uff0cRCP\uff09\u7ec4\u6210\u3002RAMP-1\u662f\u4e00\u7c7b\u5c0f\u5206\u5b50\u8de8\u819c\u86cb\u767d\uff0c\u4ee5\u5206\u5b50\u4f34\u4fa3\u7684\u5f62\u5f0f\u4ecb\u5bfcCLR\u7684\u819c\u8f6c\u4f4d\u3002RCP\u662f\u4e00\u7c7b\u5c0f\u5206\u5b50\u591a\u80bd\uff0c\u4ecb\u5bfcCLR\u4e0b\u6e38\u4fe1\u53f7\u4f20\u5bfc\u3002CGRP\u4e0e\u4e09\u53c9\u795e\u7ecf\u8840\u7ba1\u7cfb\u7edf\u7684CGRP\u53d7\u4f53\u7279\u5f02\u6027\u7ed3\u5408\uff0c\u5f15\u8d77\u795e\u7ecf\u6e90\u6027\u708e\u75c7\u3001\u795e\u7ecf\u654f\u5316\u548c\u8c03\u8282\u57fa\u56e0\u7684\u8868\u8fbe\uff0c\u89e6\u53d1\u504f\u5934\u75db\u7684\u53d1\u4f5c\uff0c\u4e14\u6709\u76f8\u5173\u4f5c\u7528\u673a\u5236\u7684\u63d0\u51fa\u548c\u5b9e\u9a8c\u7684\u7814\u7a76<\/span>[20]<\/span><\/sup><\/span>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Ajovy\u00ae<\/span><\/sup>\u662f\u4e00\u79cd\u9776\u5411\u4e8e\u964d\u9499\u7d20\u57fa\u56e0\u76f8\u5173\u80bd\uff08CGRP\uff09\u7684\u5168\u4eba\u6e90\u5316IgG2\u0394a\/kappa\u578b\u5355\u514b\u9686\u6297\u4f53\uff0cFremanezumab\u662f\u901a\u8fc7\u91cd\u7ec4DNA\u6280\u672f\u5728\u4e2d\u56fd\u4ed3\u9f20\u5375\u5de2\uff08CHO\uff09\u7ec6\u80de\u4e2d\u4ea7\u751f\u7684\u3002\u6297\u4f53\u75311324\u6c28\u57fa\u9178\u7ec4\u6210\uff0c\u5176\u5206\u5b50\u91cf\u7ea6\u4e3a148 kDa[21]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

Ajovy\u00ae<\/span><\/sup>\u7684\u83b7\u6279\u662f\u57fa\u4e8e\u4e34\u5e8a\u4e09\u671f\u5f00\u53d1\u9879\u76eeHALO\u7684\u6570\u636e\u3002\u8be5\u9879\u76ee\u5305\u62ec\u4e24\u4e2a\u5173\u952e\u6027\u4e09\u671f\u4e34\u5e8a\u7814\u7a76\uff08HALO-EM\uff0cHALO-CM\uff09\uff0c\u5165\u7ec4\u8d85\u8fc72000\u4f8b\u53d1\u4f5c\u6027\u504f\u5934\u75db\uff08EM\uff09\u548c\u6162\u6027\u504f\u5934\u75db\uff08CM\uff09\u60a3\u8005\uff0c\u8bc4\u4f30\u4e86\u6bcf\u6708\u4e00\u6b21\u548c\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04Ajovy\u00ae<\/span><\/sup>\u4f5c\u4e3a\u5355\u836f\u7597\u6cd5\u4ee5\u53ca\u4e0e\u53e3\u670d\u9884\u9632\u6027\u836f\u7269\u8054\u5408\u7528\u836f\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u6765\u81ea\u8be5\u9879\u76ee\u7684\u6570\u636e\u663e\u793a\uff0c\u6cbb\u759712\u5468\u671f\u95f4\uff0c\u4e0e\u5b89\u6170\u5242\u7ec4\u76f8\u6bd4\uff0cAjovy\u00ae<\/span><\/sup>\u6cbb\u7597\u7ec4\u60a3\u8005\u5728\u5168\u90e8\u4e3b\u8981\u548c\u6b21\u8981\u7ec8\u70b9\u4ee5\u53ca\u5728\u6240\u6709\u9884\u5148\u6307\u5b9a\u7684\u5206\u6790\u4e2d\u5747\u5b9e\u73b0\u4e86\u4e34\u5e8a\u610f\u4e49\u548c\u7edf\u8ba1\u5b66\u610f\u4e49\u7684\u663e\u8457\u6539\u5584\uff0c\u5305\u62ec\uff1a\u6bcf\u6708\u504f\u5934\u75db\u548c\u5934\u75db\u5929\u6570\u663e\u8457\u51cf\u5c11\u3001\u6025\u6551\u7528\u836f\u548c\u6b8b\u75be\u663e\u8457\u51cf\u5c11\u3001\u751f\u6d3b\u8d28\u91cf\u663e\u8457\u6539\u5584\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u6700\u5e38\u89c1\u7684\u4e0d\u826f\u4e8b\u4ef6\u4e3a\u6ce8\u5c04\u90e8\u4f4d\u786c\u7ed3\u3001\u7ea2\u6591\u548c\u7619\u75d2\uff0c\u5b89\u6170\u5242\u7ec4\u548cAjovy\u00ae<\/span><\/sup>\u6cbb\u7597\u7ec4\u53d1\u751f\u7387\u76f8\u4f3c[22]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

Ajovy\u00ae<\/span><\/sup>\u662f\u76ee\u524d\u9996\u4e2a\u4e5f\u662f\u552f\u4e00\u4e00\u4e2a\u53ef\u540c\u65f6\u6bcf\u5b63\u5ea6\u4e00\u6b21\u548c\u6bcf\u6708\u4e00\u6b21\u7ed9\u836f\u7684\u6297CGRP\u504f\u5934\u75db\u836f\u7269\uff0c\u662fFDA\u6279\u51c6\u7528\u4e8e\u6210\u4eba\u504f\u5934\u75db\u9884\u9632\u6027\u6cbb\u7597\u7684\u7b2c\u4e8c\u79cd\u6297CGRP\u5355\u514b\u9686\u6297\u4f53\u3002\u76ee\u524d\uff0c\u5728\u504f\u5934\u75db\u6cbb\u7597\u65b9\u9762\uff0c\u9884\u9632\u6027\u6cbb\u7597\u65b9\u6848\u5f88\u6709\u9650\uff0cAjovy\u00ae<\/span><\/sup>\u5c06\u4e3a\u533b\u751f\u548c\u60a3\u8005\u63d0\u4f9b\u4e00\u79cd\u91cd\u8981\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

6<\/span>Moxetumomab pasudotox<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Moxetumomabpasudotox\u7531\u963f\u65af\u5229\u5eb7\u516c\u53f8\u7814\u53d1\uff0c\u4e8e2018\u5e749\u670813\u65e5\u83b7\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aLumoxiti\u00ae<\/span><\/sup>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\u3002\u8be5\u4ea7\u54c1\u83b7FDA\u4f18\u5148\u5ba1\u8bc4\u8d44\u683c\uff0c2013\u5e74\u88ab\u6b27\u6d32EMA\u8ba4\u8bc1\u4e3a\u6cbb\u7597B\u6dcb\u5df4\u7ec6\u80de\u6027\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u7684\u5b64\u513f\u836f[23]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\uff08HCL\uff09\u662f\u4e00\u79cd\u7f55\u89c1\u7684\uff0c\u6162\u6027\u7684\u548c\u751f\u957f\u7f13\u6162\u7684\u767d\u8840\u75c5\uff0c\u5176\u4e2d\u9aa8\u9ad3\u8fc7\u91cf\u4ea7\u751f\u5f02\u5e38\u7684B\u7ec6\u80de\u6dcb\u5df4\u7ec6\u80de\uff0c\u662f\u4e00\u79cd\u5c11\u89c1\u7684B\u6dcb\u5df4\u7ec6\u80de\u80bf\u7624\u3002\u5e38\u4ee5\u5168\u8840\u7ec6\u80de\u51cf\u5c11\u548c\u813e\u810f\u80bf\u5927\u4e3a\u7279\u70b9\uff0c\u7ea6\u5360\u5168\u90e8\u767d\u8840\u75c5\u76842%\u3002HCL\u60a3\u8005\u5e38\u4f34\u6709\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u7684\u4e00\u4e9b\u8868\u73b0\uff0c\u5982\u5173\u8282\u708e\u7684\u75c7\u72b6\u3001\u5173\u8282\u75db\u3001\u76ae\u80a4\u7ea2\u6591\u3001\u76ae\u80a4\u635f\u5bb3\u3001\u4f4e\u70ed\u7b49\uff0c\u8fd9\u4e9b\u75c7\u72b6\u4e0e\u80bf\u7624\u8d1f\u8377\u65e0\u5173\uff0c\u5e38\u4e3a\u81ea\u9650\u6027\u7684\uff0c\u76ae\u8d28\u6fc0\u7d20\u6cbb\u7597\u6709\u6548\u3002HCL\u7684\u4e2d\u4f4d\u53d1\u75c5\u5e74\u9f84\u4e3a50\u5c81\uff0c\u5c1a\u65e0\u513f\u7ae5\u6216\u9752\u5c11\u5e74\u53d1\u75c5\u62a5\u9053\u3002\u7ea680%\u7684\u60a3\u8005\u4e3a\u7537\u6027\u3002\u5c31\u8bca\u65f6\u7ea61\/4\u7684\u60a3\u8005\u4e3b\u8bc9\u4e3a\u813e\u810f\u80bf\u5927\u6240\u81f4\u7684\u8179\u90e8\u80c0\u6ee1\u6216\u4e0d\u9002\uff1b1\/4\u7684\u60a3\u8005\u6709\u75b2\u4e4f\u65e0\u529b\u3001\u4f53\u91cd\u4e0b\u964d\uff1b1\/4\u7684\u60a3\u8005\u6709\u8840\u5c0f\u677f\u51cf\u5c11\u5f15\u8d77\u7684\u51fa\u8840\u8d8b\u52bf\u6216\u7ee7\u53d1\u4e8e\u7c92\u7ec6\u80de\u548c\u5355\u6838\u7ec6\u80de\u51cf\u5c11\u7684\u6613\u611f\u67d3\u503e\u5411\uff1b\u5176\u4ed6\u60a3\u8005\u53ef\u80fd\u5728\u67e5\u4f53\u65f6\u53d1\u73b0\u8840\u7ec6\u80de\u8ba1\u6570\u5f02\u5e38\u6216\u813e\u810f\u80bf\u5927[24]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Lumoxiti\u00ae<\/span><\/sup>\u7684\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u5355\u81c2\u7684\u5f00\u653e\u6027\u7684\u4e34\u5e8a\u4e09\u671f\u8bd5\u9a8c\uff0c\u8be5\u8bd5\u9a8c\u5bf980\u540d\u81f3\u5c11\u4e24\u6b21\u63a5\u53d7\u8fc7HCL\u6cbb\u7597\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u5168\u8eab\u6cbb\u7597\u3002\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u6301\u4e45\u7684\u5b8c\u5168\u53cd\u5e94\uff0c\u8bd5\u9a8c\u4e2d30\uff05\u7684\u60a3\u8005\u8fbe\u5230\u6301\u4e45CR\uff0c\u603b\u4f53\u53cd\u5e94\u7387\uff08\u5bf9\u6cbb\u7597\u6709\u90e8\u5206\u6216\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6570\uff09\u4e3a75\uff05\u3002\u8840\u6db2\u5b66\u7f13\u89e3\u7387\u4e3a80%[25]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u8bb8\u591a\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\u60a3\u8005\u901a\u8fc7\u73b0\u6709\u6cbb\u7597\u53ef\u4ee5\u83b7\u5f97\u7f13\u89e3\uff0c\u4f46\u662f30\uff05\u81f340\uff05\u5c06\u5728\u9996\u6b21\u6cbb\u7597\u540e5\u81f310\u5e74\u518d\u6b21\u590d\u53d1\u3002\u968f\u540e\u7684\u6cbb\u7597\uff0c\u53cd\u5e94\u6301\u7eed\u65f6\u95f4\u51cf\u5c11\uff0c\u6bd2\u6027\u79ef\u7d2f\uff0c\u5f88\u5c11\u6709\u6279\u51c6\u7684\u6cbb\u7597\u65b9\u6848\u3002Lumoxiti\u00ae<\/span><\/sup>\u4f5c\u4e3a\u4e00\u79cd\u91cd\u7ec4\u7684\u9776\u5411\u4e8eCD22\u7684\u6297\u6bd2\u7d20\uff0c\u662f\u7f8e\u56fd\u9488\u5bf9\u590d\u53d1\u6216\u96be\u6cbb\u6027\u6bdb\u7ec6\u80de\u767d\u8840\u75c5\uff08HCL\uff09\u6210\u5e74\u60a3\u8005\u7684\u4e00\u6d41\u6cbb\u7597\u836f\u7269\uff0c\u662f\u4e00\u79cd\u6709\u524d\u666f\u7684HCL\u975e\u5316\u7597\u836f\u7269\uff0c\u53ef\u89e3\u51b3\u533b\u751f\u53ca\u5176\u60a3\u8005\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

7<\/span>Gilteritinib fumarate<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Gilteritinib fumarate\u7531\u5b89\u65af\u6cf0\u6765\u7814\u53d1\uff0c\u4e8e2018\u5e749\u670821\u65e5\u83b7\u65e5\u672c\u533b\u836f\u54c1\u533b\u7597\u5668\u68b0\u7efc\u5408\u673a\u6784\uff08PMDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aXospata\u00ae<\/span><\/sup>\u3002\u5b83\u662f\u4e00\u79cdFLT3\/AXL\u6291\u5236\u5242\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597FLT3\u7a81\u53d8\u9633\u6027\u7684\u590d\u53d1\u6216\u96be\u6cbb\u6027\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5[26]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u6025\u6027\u9ad3\u7ec6\u80de\u6027\u767d\u8840\u75c5\uff08Acute myeloid leukemia\uff0cAML\uff09\u662f\u4e00\u7ec4\u9ad8\u5ea6\u5f02\u8d28\u6027\u7684\u514b\u9686\u6027\u75be\u60a3\uff0c\u5177\u6709\u72ec\u7279\u7684\u7ec6\u80de\u5f62\u6001\u5b66\u3001\u514d\u75ab\u8868\u578b\u3001\u7ec6\u80de\u9057\u4f20\u5b66\u53ca\u5206\u5b50\u9057\u4f20\u5b66\u7279\u5f81\u3002\u4e00\u4e9b\u91cd\u73b0\u6027\u57fa\u56e0\u7a81\u53d8\u5df2\u88ab\u8bc1\u5b9e\u662fAML\u8bca\u65ad\u5206\u578b\u3001\u5371\u9669\u5206\u5c42\u53ca\u8bc4\u4f30\u9884\u540e\u7684\u91cd\u8981\u56e0\u7d20\uff0c\u5e76\u4e14\u4e00\u4e9b\u9488\u5bf9\u7a81\u53d8\u57fa\u56e0\u7684\u7279\u5f02\u6027\u9776\u5411\u836f\u7269\u4e5f\u9010\u6e10\u8fdb\u5165\u4e34\u5e8a\u7814\u7a76[27]<\/span><\/sup>\u3002\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08AML\uff09\u5360\u6025\u6027\u767d\u8840\u75c5\u768450\uff05\u4ee5\u4e0a\uff0c\u4ee540\u5c81\u7684\u6210\u5e74\u4eba\u591a\u89c1\uff0c\u53d1\u75c5\u7387\u968f\u5e74\u9f84\u589e\u957f\u800c\u4e0a\u5347\u3002\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u4f1a\u5bfc\u81f4\u60a3\u8005\u51fa\u73b0\u8d2b\u8840\u3001\u51fa\u8840\u3001\u53d1\u70ed\u7b49\u4e34\u5e8a\u75c7\u72b6\uff0c\u4e0d\u4ec5\u4e0d\u5229\u4e8e\u60a3\u8005\u8eab\u4f53\u5065\u5eb7\uff0c\u800c\u4e14\u8fd8\u4f1a\u5bf9\u60a3\u8005\u7684\u751f\u547d\u5b89\u5168\u6784\u6210\u5a01\u80c1[28]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Xospata\u00ae<\/span><\/sup>\u7684\u83b7\u6279\u662f\u57fa\u4e8e\u5bf9\u5728\u591a\u56fd\u8fdb\u884c\u7684\u4e34\u5e8a\u4e09\u671f\u8bd5\u9a8c\uff08NCT02421939\uff09\u7814\u7a76\u7684\u4e2d\u671f\u7ed3\u679c\u7684CR\/CRh2\u5206\u6790\u3002ADIMRAL\u7684\u76ee\u7684\u662f\u6bd4\u8f83Xospata\u00ae<\/span><\/sup>\u4e0e\u633d\u6551\u6027\u5316\u7597\u5728\u6709FLT3\u7a81\u53d8\u5e76\u5df2\u590d\u53d1\u7684\u6216\u96be\u6cbb\u6027\u6210\u4ebaAML\u7684\u4e00\u7ebf\u6cbb\u7597\u3002\u60a3\u8005\u63092:1\u7684\u6bd4\u4f8b\u968f\u673a\u63a5\u53d7Xospata\u00ae<\/span><\/sup> (120mg)\u6216\u633d\u6551\u6027\u5316\u7597\uff0cXospata\u00ae<\/span><\/sup>\u5df2\u7ecf\u8bc1\u660e\u5177\u6709\u6291\u5236FLT3\u5185\u4e32\u8054\u590d\u5236\u548cFLT\u916a\u6c28\u9178\u6fc0\u9176\u7ed3\u6784\u57df\u7a81\u53d8\u7684\u6d3b\u6027\u3002\u8fd9\u4e24\u4e2a\u7a81\u53d8\u5b58\u5728\u4e8e\u5927\u7ea6\u4e09\u5206\u4e4b\u4e00\u7684AML\u60a3\u8005\u4e2d[29]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u76f8\u5bf9\u4e8e\u5176\u4ed6\u7684\u764c\u75c7\uff0c\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u8fd8\u662f\u6bd4\u8f83\u7f55\u89c1\u7684\u75be\u75c5\uff1a\u4e2d\u56fd\u53d1\u75c5\u7387\u4e3a1.62\/10\u4e07\uff0c\u4f4e\u4e8e\u7f8e\u56fd\u53d1\u75c5\u73874.36-6.13\/10\u4e07\u548c\u65e5\u672c3.25-5.85\/10\u4e07\u3002\u867d\u7136\u53ef\u4ee5\u662f\u539f\u53d1\u6027\u7684\uff0c\u4e5f\u53ef\u80fd\u662f\u7ee7\u53d1\u6027\u7684\uff0c\u56e0\u4e3a\u653e\u5c04\u7ebf\u66b4\u9732\u3001\u81f4\u764c\u5316\u5b66\u836f\u7269\u66b4\u9732\u9020\u6210\uff0c\u6216\u66fe\u7ecf\u6709\u5176\u4ed6\u8840\u6db2\u75be\u75c5\uff0c\u5982\u9aa8\u9ad3\u5316\u751f\u4e0d\u826f\u75c7\u5019\u7fa4\uff08myelodysplastic syndrome\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u6027\u75be\u75c5\uff08myeloproliferative disorder\uff09\u6f14\u53d8\u800c\u6210\u3002\u60a3\u8005\u4eba\u7fa4\u4e2d\u7537\u6027\u8f83\u5973\u6027\u7565\u9ad8\u3002Xospata\u00ae<\/span><\/sup>\u7684\u4e0a\u5e02\u4e3a\u6cbb\u6108\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u63d0\u4f9b\u4e86\u65b0\u7684\u9009\u62e9\u65b9\u6848[30]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

8<\/span>Anagliptin\/ Metformin Hydrochloride<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

\u5b89\u5948\u683c\u5217\u6c40\/\u76d0\u9178\u4e8c\u7532\u53cc\u80cd\u7531Suzuken\u7684\u5b50\u516c\u53f8\u4e09\u548c\u5316\u5b66\u7814\u7a76\u6240\u7814\u53d1\uff0c\u4e8e2018\u5e749\u670821\u65e5\u83b7\u65e5\u672c\u533b\u836f\u54c1\u533b\u7597\u5668\u68b0\u7efc\u5408\u673a\u6784\uff08PMDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aMetoana\u00ae<\/span><\/sup>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5[31]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

2\u578b\u7cd6\u5c3f\u75c5\u539f\u540d\u53eb\u6210\u4eba\u53d1\u75c5\u578b\u7cd6\u5c3f\u75c5\uff0c\u591a\u572835\uff5e40\u5c81\u4e4b\u540e\u53d1\u75c5\uff0c\u662f\u4e00\u79cd\u6162\u6027\u4ee3\u8c22\u75be\u75c5\uff0c\u5360\u7cd6\u5c3f\u75c5\u60a3\u800590%\u4ee5\u4e0a\u30022\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f53\u5185\u4ea7\u751f\u80f0\u5c9b\u7d20\u7684\u80fd\u529b\u5e76\u975e\u5b8c\u5168\u4e27\u5931\uff0c\u6709\u7684\u60a3\u8005\u4f53\u5185\u80f0\u5c9b\u7d20\u751a\u81f3\u4ea7\u751f\u8fc7\u591a\uff0c\u4f46\u80f0\u5c9b\u7d20\u7684\u4f5c\u7528\u6548\u679c\u8f83\u5dee\uff0c\u56e0\u6b64\u60a3\u8005\u4f53\u5185\u7684\u80f0\u5c9b\u7d20\u662f\u4e00\u79cd\u76f8\u5bf9\u7f3a\u4e4f\uff0c\u53ef\u4ee5\u901a\u8fc7\u67d0\u4e9b\u53e3\u670d\u836f\u7269\u523a\u6fc0\u4f53\u5185\u80f0\u5c9b\u7d20\u7684\u5206\u6ccc\u3002\u4f46\u5230\u540e\u671f\u4ecd\u6709\u4e00\u4e9b\u75c5\u4eba\u9700\u8981\u4f7f\u7528\u80f0\u5c9b\u7d20\u6cbb\u7597\u30022\u578b\u7cd6\u5c3f\u75c5\u4e2d\u4e00\u90e8\u5206\u75c5\u4eba\u4ee5\u80f0\u5c9b\u7d20\u62b5\u6297\u4e3a\u4e3b\uff0c\u75c5\u4eba\u591a\u80a5\u80d6\uff0c\u56e0\u80f0\u5c9b\u7d20\u62b5\u6297\uff0c\u80f0\u5c9b\u7d20\u654f\u611f\u6027\u4e0b\u964d\uff0c\u8840\u4e2d\u80f0\u5c9b\u7d20\u589e\u9ad8\u4ee5\u8865\u507f\u5176\u80f0\u5c9b\u7d20\u62b5\u6297\uff0c\u4f46\u76f8\u5bf9\u75c5\u4eba\u7684\u9ad8\u8840\u7cd6\u800c\u8a00\uff0c\u80f0\u5c9b\u7d20\u5206\u6ccc\u4ecd\u76f8\u5bf9\u4e0d\u8db3\u3002\u6b64\u7c7b\u75c5\u4eba\u65e9\u671f\u75c7\u72b6\u4e0d\u660e\u663e\uff0c\u4ec5\u6709\u8f7b\u5ea6\u4e4f\u529b\u3001\u53e3\u6e34\uff0c\u5e38\u5728\u660e\u786e\u8bca\u65ad\u4e4b\u524d\u5c31\u53ef\u53d1\u751f\u5927\u8840\u7ba1\u548c\u5fae\u8840\u7ba1\u5e76\u53d1\u75c7\u3002\u996e\u98df\u6cbb\u7597\u548c\u53e3\u670d\u964d\u7cd6\u836f\u591a\u53ef\u6709\u6548\u3002\u53e6\u4e00\u90e8\u5206\u75c5\u4eba\u4ee5\u80f0\u5c9b\u7d20\u5206\u6ccc\u7f3a\u9677\u4e3a\u4e3b\uff0c\u4e34\u5e8a\u4e0a\u9700\u8981\u8865\u5145\u5916\u6e90\u6027\u80f0\u5c9b\u7d20[32]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

\u5b89\u5948\u683c\u5217\u6c40\u662f\u4e00\u79cd\u957f\u6548\u9009\u62e9\u6027\u4e8c\u80bd\u57fa\u80bd\u9176-4 \uff08DPP-4\uff09\u6291\u5236\u5242\uff0c\u80fd\u6709\u6548\u6291\u5236DPP-4\u6d3b\u6027\uff0c\u4f7f\u9910\u540e\u5206\u6ccc\u7684\u80f0\u9ad8\u8840\u7cd6\u7d20\u6837\u80bd-1 \uff08GLP-1\uff09\u548cGIP\u4e0d\u88abDPP-4\u964d\u89e3\uff0c\u5ef6\u957fGLP-1\u548cGIP\u4f5c\u7528\u65f6\u95f4\uff0c\u4fc3\u8fdb\u80f0\u5c9b\u7d20\u91ca\u653e\uff0c\u964d\u4f4e\u9910\u540e\u8840\u7cd6\u3002\u76d0\u9178\u4e8c\u7532\u53cc\u80cd\u662f\u4e00\u79cd\u53cc\u80cd\u7c7b\u6297\u7cd6\u5c3f\u75c5\u836f\uff0c\u7ecf\u53e3\u7ed9\u836f\uff0c\u7528\u4e8e2\u578b\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7597\uff0c\u5e76\u4e14\u662f\u8d85\u91cd\u60a3\u8005\u7684\u9996\u9009\u836f\u7269\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u8054\u5408\u7528\u836f\u7684\u590d\u65b9\u5236\u5242\u662f\u8fd1\u4e24\u5e74\u4e0a\u5e02\u7684\u4ee5\u53ca\u665a\u671f\u7684\u7814\u53d1\u9879\u76ee\u70ed\u70b9\u4e4b\u4e00\uff0c\u5e76\u5c06\u6210\u4e3a\u672a\u6765\u7cd6\u5c3f\u75c5\u7528\u7a76\u7684\u5927\u65b9\u5411\u3002\u76ee\u524d\u4e34\u5e8a\u665a\u671f\u9879\u76ee\u7684\u4e3b\u8981\u65b9\u5411\u662f\uff1aSGLT-2\u6291\u5236\u5242\u4e0e\u4e8c\u7532\u53cc\u80cd\u7684\u590d\u65b9\u5236\u5242\uff0cDPP-4\u4e0eSGLT-2\u6291\u5236\u5242\u7684\u590d\u65b9\u5236\u5242\uff0c\u4ee5\u53ca\u80f0\u5c9b\u7d20\u4e0eGLP-1\u6fc0\u52a8\u5242\u7684\u8054\u5408\u7528\u836f\u5f00\u53d1\u3002\u590d\u65b9\u5236\u5242\u7684\u597d\u5904\u662f\u663e\u800c\u6613\u89c1\u7684\uff1a\u7531\u4e8e\u4e24\u79cd\u836f\u7269\u9488\u5bf9\u7684\u53d1\u75c5\u673a\u5236\u4e0d\u4e00\u6837\uff0c\u8054\u5408\u534f\u540c\u53ef\u4ee5\u9488\u5bf92\u578b\u7cd6\u5c3f\u75c5\u7684\u4e0d\u540c\u53d1\u75c5\u673a\u5236\u548c\u75c5\u7406\u73af\u8282\u8fdb\u884c\u6cbb\u7597\uff1b\u4e24\u79cd\u836f\u7269\u8054\u5408\u4e0d\u589e\u52a0\u7cd6\u5c3f\u75c5\u75c5\u4eba\u7684\u4f53\u91cd\uff0c\u90e8\u5206\u75c5\u4eba\u8fd8\u53ef\u51cf\u8f7b\u4f53\u91cd\uff1b\u590d\u65b9\u5236\u5242\u51cf\u5c11\u75c5\u4eba\u670d\u7528\u836f\u7247\u6570\u91cf\uff0c\u589e\u52a0\u60a3\u8005\u4f9d\u4ece\u6027[33]<\/span><\/sup>\u3002Metoana\u00ae<\/span><\/sup>\u7684\u4e0a\u5e02\u4e3a\u7cd6\u5c3f\u75c5\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u591a\u7684\u9009\u62e9\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

9<\/span>Lorlatinib<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Lorlatinib\u662f\u8f89\u745e\u7814\u53d1\u7684\u5c0f\u5206\u5b50\u6297\u764c\u836f\uff0c\u4e8e2018\u5e749\u670821\u65e5\u83b7\u65e5\u672c\u533b\u836f\u54c1\u533b\u7597\u5668\u68b0\u7efc\u5408\u673a\u6784\uff08PMDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aLorbrena\u00ae<\/span><\/sup>\uff0c\u83b7\u6279\u7528\u4e8e\u6cbb\u7597ALK\u878d\u5408\u57fa\u56e0\u9633\u6027\u65e0\u6cd5\u5207\u9664\u7684\u590d\u53d1\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c[34]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u95f4\u53d8\u6027\u6dcb\u5df4\u7624\u6fc0\u9176(anaplasticlymphomakinase\uff0cALK)\u9633\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c(non-small celllung cancer\uff0cNSCLC)\u662f\u80ba\u764c\u7684\u4e00\u4e2a\u91cd\u8981\u4e9a\u578b\uff0c\u95f4\u53d8\u6027\u6dcb\u5df4\u7624\u6fc0\u9176\uff08anaplastic  lymphoma kinase,ALK\uff09\u57fa\u56e0\u91cd\u6392\u662f\u53d1\u751f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer,NSCLC\uff09\u7684\u91cd\u8981\u81f4\u764c\u9a71\u52a8\u56e0\u7d20\u4e4b\u4e00\uff0cALK\u9633\u6027\u7684NSCLC\u60a3\u8005\u6613\u53d1\u751f\u8111\u8f6c\u79fb\uff0c\u800cALK\u9776\u5411\u6291\u5236\u5242\u76f8\u5bf9\u4e8e\u4e00\u7ebf\u5316\u7597\u5bf9\u8111\u8f6c\u79fb\u6709\u66f4\u597d\u7684\u7597\u6548\u3002\u4f46\u7ecf\u7b2c\u4e00\u4ee3ALK\u6291\u5236\u5242\u6cbb\u7597\u540e\u60a3\u8005\u6613\u8010\u836f\uff0c\u8fdb\u800c\u51fa\u73b0\u9885\u5185\u8fdb\u5c55, \u7b2c\u4e8c\u4ee3\u548c\u7b2c\u4e09\u4ee3ALK\u6291\u5236\u5242\u53ef\u589e\u5f3a\u5176\u5bf9\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u7684\u6e17\u900f\u6027\u3001\u63d0\u9ad8\u5176\u5230\u8fbe\u9776\u70b9\u540e\u7684\u7ed3\u5408\u529b\uff0c\u5bf9\u8111\u8f6c\u79fb\u764c\u6709\u8f83\u597d\u7684\u6cbb\u7597\u6548\u679c[35]<\/span><\/sup>\u3002 <\/span><\/p>\n


<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n

<\/span>
<\/p>\n

Lorbrena\u00ae<\/span><\/sup>\u7684\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879I\/II\u671f\uff08NCT01970865\uff09\u7814\u7a76\u4e2d\u7684\u4e8c\u671f\u6570\u636e\uff0c\u8be5\u7814\u7a76\u8bc4\u4f30\u4e86lorlatinib\u5bf9\u63a5\u53d7\u8fc7\u4e0d\u540cALK\u6291\u5236\u5242\u60a3\u8005\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff0c\u7ed3\u679c\u66fe\u5728WCLC2017\u5927\u4f1a\u4e0a\u516c\u5e03\u3002\u7ed3\u679c\u663e\u793a\uff0clorlatinib\u4e00\u7ebf\u6cbb\u759730\u4f4d\u521d\u6cbbALK+NSCLC\u60a3\u8005\uff0cORR\u4e3a90%\uff0c\u75be\u75c5\u63a7\u5236\u738797%\uff0c\u53ea\u6709\u4e00\u4f4d\u60a3\u8005\u65e0\u6548\uff1blorlatinib\u4e8c\u7ebf\u6216\u4e09\u7ebf\u6cbb\u759759\u4f4d\u4f7f\u7528\u8fc7\u514b\u5511\u66ff\u5c3c\u6216\u8005\u514b\u5511\u66ff\u5c3c+\u5316\u7597\u7684\u60a3\u8005\uff0cORR\u9ad8\u8fbe69%\uff1b\u5bf9\u4e8e\u4f7f\u7528\u8fc72-3\u79cdALK\u6291\u5236\u5242\u5916\u52a0\u5316\u7597\u7684\u60a3\u8005\uff0clorlatinib\u4f5c\u4e3a\u4e09\u7ebf\u751a\u81f3\u4e94\u7ebf\u836f\u7269\u4f7f\u7528\uff0cORR\u4f9d\u7136\u8fbe\u523039%[36]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u8f6c\u79fb\u6027ALK\u7a81\u53d8\u9633\u6027NSCLC\u60a3\u8005\u9762\u4e34\u7684\u4e00\u5927\u6311\u6218\u662f\u5bf9\u521d\u59cb\u6cbb\u7597\u836f\u7269\u53d1\u751f\u8010\u836f\uff0c\u4f1a\u5bfc\u81f4\u75be\u75c5\u5feb\u901f\u8fdb\u5c55\u3002Lorlatinib\u53ef\u4ee5\u514b\u670d\u7b2c\u4e00\u4ee3\u548c\u7b2c\u4e8c\u4ee3ALK\u6291\u5236\u5242\u8010\u836f\uff0c\u5728\u591a\u9879\u4e34\u5e8a\u7814\u7a76\u4e2d\u83b7\u5f97\u4e86\u79ef\u6781\u7684\u7ed3\u679c\uff0cLorbrena\u00ae<\/span><\/sup>\u7684\u83b7\u6279\u610f\u5473\u7740\u60a3\u8005\u7684\u7528\u836f\u9009\u62e9\u66f4\u52a0\u4e30\u5bcc\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

10<\/span>Omidenepag isopropyl<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Omidenepag isopropyl\u662f\u7531\u65e5\u672c\u53c2\u5929\u5236\u836f\u53ca\u5b87\u90e8\u5174\u4ea7\u682a\u5f0f\u4f1a\u793e\u5408\u4f5c\u5f00\u53d1\uff0c\u4e8e2018\u5e749\u670821\u65e5\u83b7PMDA\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3aEybelis\u00ae<\/span><\/sup>\u3002Omidenepag isopropyl\u662f\u4e00\u79cd\u524d\u5217\u817a\u7d20\u53d7\u4f53\u6fc0\u52a8\u5242\uff0c\u901a\u8fc7\u653e\u677e\u776b\u72b6\u808c\u964d\u4f4e\u773c\u538b\uff0c\u5e76\u901a\u8fc7\u8461\u8404\u819c\u5de9\u819c\u9014\u5f84\u589e\u52a0\u623f\u6c34\u5916\u6d41\uff0c\u6cbb\u7597\u9752\u5149\u773c\u548c\u9ad8\u773c\u538b\u75c7[37]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u9752\u5149\u773c\u662f\u4e00\u7cfb\u5217\u4f1a\u5bfc\u81f4\u89c6\u795e\u7ecf\u53d7\u635f\uff0c\u8fdb\u800c\u9020\u6210\u89c6\u529b\u4e27\u5931\u7684\u773c\u75be\uff0c\u591a\u6570\u7cfb\u773c\u5185\u538b\u529b\u5347\u9ad8\u6240\u81f4\uff0c\u6709\u5267\u70c8\u5934\u75db\u3001\u6076\u5fc3\u3001\u5455\u5410\u7b49\u75c7\uff0c\u7531\u4e8e\u773c\u5185\u538b\u529b\u5347\u9ad8\uff0c\u4f7f\u773c\u7403\u53d1\u786c\uff0c\u800c\u5bfc\u81f4\u795d\u529b\u9aa4\u7136\u4e0b\u964d\u6216\u5931\u660e[38]<\/span><\/sup>\u3002\u9752\u5149\u773c\u662f\u5bfc\u81f4\u4eba\u7c7b\u5931\u660e\u7684\u4e09\u5927\u81f4\u76f2\u773c\u75c5\u4e4b\u4e00\uff0c\u603b\u4eba\u7fa4\u53d1\u75c5\u7387\u4e3a1%\uff0c45\u5c81\u4ee5\u540e\u4e3a2%\u3002\u4e34\u5e8a\u4e0a\u6839\u636e\u75c5\u56e0\u3001\u623f\u89d2\u3001\u773c\u538b\u63cf\u8bb0\u7b49\u60c5\u51b5\u5c06\u9752\u5149\u773c\u5206\u4e3a\u539f\u53d1\u6027\u3001\u7ee7\u53d1\u6027\u548c\u5148\u5929\u6027\u4e09\u5927\u7c7b\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u9ad8\u773c\u538b\u75c7\u662f\u773c\u538b\u9ad8\u4e8e21 mmHg\u7684\u7edf\u79f0\uff0c\u53ef\u89c1\u4e8e\u5404\u79cd\u539f\u56e0\u5982\u5916\u4f24\u6027\u524d\u623f\u51fa\u8840\u3001\u773c\u7736\u6c34\u80bf\u3001\u672f\u540e\u7c98\u5f39\u5242\u6b8b\u7559\u3001\u773c\u5185\u708e\u3001\u4f7f\u7528\u7cd6\u76ae\u8d28\u6fc0\u7d20\u3001\u77b3\u5b51L\u963b\u6ede\u548c\u7279\u53d1\u6027\u7b49\u3002\u9ad8\u773c\u538b\u75c7\u672c\u8eab\u4e0d\u662f\u4e00\u79cd\u75be\u75c5\uff0c\u5b83\u53ea\u662f\u7528\u6765\u63cf\u8ff0\u4e00\u7c7b\u4e2a\u4f53\u7684\u672f\u8bed\uff0c\u8fd9\u4e9b\u4e2a\u4f53\u6bd4\u4e00\u822c\u4eba\u7fa4\u66f4\u5e94\u53d7\u5230\u5bc6\u5207\u89c2\u5bdf\u4ee5\u65e9\u671f\u53d1\u73b0\u9752\u5149\u773c\u635f\u5bb3\u53d1\u751f[39]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Eybelis\u00ae<\/span><\/sup>\u7684\u6279\u51c6\u662f\u57fa\u4e8e\u4e24\u9879\u968f\u673a\u7684\u3001\u591a\u4e2d\u5fc3\u7684\u3001\u5f00\u653e\u6027\u6807\u7b7e\u7684\u4e34\u5e8a\u4e09\u671f\u8bd5\uff08NCT02822742\uff0cNCT02981446\uff09\u3002\u7b2c\u4e00\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u4e3b\u8981\u8bc4\u4f30\u4e86\u5bf9\u62c9\u5766\u524d\u5217\u7d20\u6ef4\u773c\u6db2\u65e0\u5e94\u7b54\u8005\u4f4e\u5e94\u7b54\u7684\u539f\u53d1\u6027\u5f00\u89d2\u578b\u9752\u5149\u773c\u53ca\u773c\u538b\u8fc7\u9ad8\u60a3\u8005\u5728\u4f7f\u7528Eybelis\u00ae<\/span><\/sup>\u540e\u7684\u5b89\u5168\u6027\u53ca\u6709\u6548\u6027\uff0c\u8be5\u8bd5\u9a8c\u7684\u9996\u8981\u6cbb\u7597\u7ec8\u70b9\u662f\u5bf9\u773c\u538b\u7684\u6709\u6548\u63a7\u5236\uff0c\u5728\u7b2c\u4e8c\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c\u4e3b\u8981\u5bf9\u6bd4\u4e86Eybelis\u00ae<\/span><\/sup>\u548c\u62c9\u5766\u524d\u5217\u7d20\u6ef4\u773c\u6db2\u5728\u5f00\u89d2\u578b\u9752\u5149\u773c\u53ca\u773c\u538b\u8fc7\u9ad8\u60a3\u8005\u4e2d\u4f7f\u7528\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u7684\u8bc4\u4f30\u3002\u8be5\u8bd5\u9a8c\u7684\u9996\u8981\u6cbb\u7597\u7ec8\u70b9\u662f\u5e73\u5747\u663c\u591c\u538b\u3002\u4e24\u9879\u8bd5\u9a8c\u5747\u5f97\u5230\u4e86\u4e0d\u52a3\u4e8e\u9633\u6027\u5bf9\u7167\u7ec4\u7684\u7597\u6548\u7ed3\u679c\uff0c\u5b9e\u73b0\u4e86\u5bf9\u773c\u538b\u7684\u6709\u6548\u63a7\u5236\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u773c\u538b\u4e0b\u964d\u662f\u76ee\u524d\u6cbb\u7597\u9752\u5149\u773c\u75be\u75c5\u6700\u53ef\u9760\u7684\u65b9\u6cd5\uff0c\u7ecf\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u663e\u793aEybelis\u00ae<\/span><\/sup>\u53ef\u4ee5\u6709\u6548\u7684\u63a7\u5236\u773c\u538b\uff0cEybelis\u00ae<\/span><\/sup>\u7684\u4e0a\u5e02\u4e3a\u6cbb\u7597\u5f00\u89d2\u578b\u9752\u5149\u773c\u53ca\u773c\u538b\u8fc7\u9ad8\u63d0\u4f9b\u4e86\u66f4\u591a\u6709\u6548\u7684\u9009\u62e9\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n

11<\/span>Fruquintinib (\u544b\u55b9\u66ff\u5c3c)<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

\"2018\u5e749\u6708\u5168\u7403\u6279\u51c6\u65b0\u836f\u6982\u51b5\"<\/p>\n


<\/p>\n

Fruquintinib\uff08\u544b\u55b9\u66ff\u5c3c\uff09\u4e8e2018\u5e749\u67085\u65e5\u83b7NMPA\uff08\u539fCFDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u5546\u54c1\u540d\u4e3a\u7231\u4f18\u7279\u00ae<\/span><\/sup>\uff0c\u7528\u4e8e\u6cbb\u7597\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u3002\u544b\u55b9\u66ff\u5c3c\u662f\u4e00\u79cd\u9ad8\u9009\u62e9\u6027\u7684\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08VEGFR\uff09\u53e3\u670d\u6291\u5236\u5242\uff0c\u6709\u6f5c\u529b\u6210\u4e3a\u5168\u7403\u540c\u7c7b\u6700\u4f73\u7684\u80fd\u591f\u6cbb\u7597\u591a\u79cd\u5b9e\u4f53\u7624\u7684VEGFR\u6291\u5236\u5242\u3002\u9ad8\u6548\u3001\u4f4e\u6bd2\u3001\u9002\u5408\u8054\u5408\u7528\u836f\u662f\u544b\u55b9\u66ff\u5c3c\u533a\u522b\u4e8e\u5176\u4ed6\u5df2\u83b7\u6279\u7684\u5c0f\u5206\u5b50VEGFR\u6291\u5236\u5242\u7684\u4f18\u826f\u7279\u6027[40]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u7ed3\u80a0\u76f4\u80a0\u764c\u662f\u6700\u5e38\u89c1\u7684\u6076\u6027\u80bf\u7624\u4e4b\u4e00\uff0c\u5176\u53d1\u75c5\u7387\u5728\u5168\u4e16\u754c\u8303\u56f4\u5185\u5c45\u6076\u6027\u80bf\u7624\u7b2c3\u4f4d\uff0c\u6b7b\u4ea1\u7387\u4e5f\u5c45\u7b2c3\u4f4d\u3002\u7ed3\u80a0\u76f4\u80a0\u764c\u5728\u6211\u56fd\u7684\u53d1\u75c5\u7387\u5448\u4e0a\u5347\u8d8b\u52bf\uff0c\u76ee\u524d\u7ea6\u4e07\u5206\u4e4b\u4e8c\u81f3\u4e09\u3002\u5176\u4e2d\u4e0a\u6d77\u5730\u533a\u5df2\u4e0a\u5347\u81f3\u7b2c2\u4f4d[41]<\/span><\/sup>\u3002\u8bca\u65ad\u65f6\uff0c50%\uff5e60%\u7684\u80bf\u7624\u8f6c\u79fb\uff0c\u9884\u540e\u8f83\u5dee\u3002\u5316\u7597\u88ab\u8ba4\u4e3a\u662f\u7ed3\u76f4\u80a0\u764c\u7684\u6807\u51c6\u6cbb\u7597\uff0c\u4f46\u5316\u7597\u7684\u5c40\u9650\u6027\u4e0d\u5bb9\u5ffd\u89c6\uff0c\u5982\u9009\u62e9\u6027\u4f4e\u3001\u80bf\u7624\u7ec4\u7ec7\u6d53\u5ea6\u4e0d\u8db3\u3001\u5168\u8eab\u6bd2\u6027\u7b49[42]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n

<\/span>
<\/p>\n

\u7231\u4f18\u7279\u00ae<\/span><\/sup>\u5355\u836f\u9002\u7528\u4e8e\u65e2\u5f80\u63a5\u53d7\u8fc7\u6c1f\u5c3f\u5627\u5576\u7c7b\u3001\u5965\u6c99\u5229\u94c2\u548c\u4f0a\u7acb\u66ff\u5eb7\u4e3a\u57fa\u7840\u7684\u5316\u7597\uff0c\u4ee5\u53ca\u65e2\u5f80\u63a5\u53d7\u8fc7\u6216\u4e0d\u9002\u5408\u63a5\u53d7\u6297\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\uff08VEGF\uff09\u6cbb\u7597\u3001\u6297\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08EGFR\uff09\u6cbb\u7597\uff08RAS\u91ce\u751f\u578b\uff09\u7684\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u60a3\u8005\u3002\u544b\u55b9\u66ff\u5c3c\u662f\u55b9\u5511\u5549\u7c7b\u5c0f\u5206\u5b50\u8840\u7ba1\u751f\u6210\u6291\u5236\u5242\uff0c\u901a\u8fc7\u4f5c\u7528VEGFR\u6fc0\u9176\u5bb6\u65cf\u6765\u6291\u5236\u8840\u7ba1\u5185\u76ae\u7ec6\u80de\u7684\u589e\u6b96\u3001\u8fc1\u79fb\u548c\u7ba1\u8154\u5f62\u6210\uff0c\u4ece\u800c\u6291\u5236\u80bf\u7624\u65b0\u751f\u8840\u7ba1\u5f62\u6210\u53ca\u80bf\u7624\u751f\u957f\uff0c\u4e3a\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u60a3\u8005\u63d0\u4f9b\u65b0\u7684\u6cbb\u7597\u9014\u5f84[43]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

FRESCO\u7814\u7a76\u662f\u56fd\u5185\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u7684\u544b\u55b9\u66ff\u5c3c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u7eb3\u5165\u4e8c\u7ebf\u6216\u4ee5\u4e0a\u6807\u51c6\u5316\u7597\u5931\u8d25\u7684\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u60a3\u8005\uff0c\u4ee52\uff1a1\u968f\u673a\u5165\u7ec4\uff0c\u6700\u7ec8278\u4f8b\u60a3\u8005\u8fdb\u5165\u544b\u55b9\u66ff\u5c3c\u8054\u5408\u6700\u4f73\u652f\u6301\u6cbb\u7597\u7ec4\uff0c138\u4f8b\u60a3\u8005\u8fdb\u5165\u5b89\u6170\u5242\u8054\u5408\u6700\u4f73\u652f\u6301\u6cbb\u7597\u7ec4\u3002\u8be5\u7814\u7a76\u8fbe\u5230\u4e3b\u8981\u7ec8\u70b9\u548c\u6240\u6709\u6b21\u8981\u7ec8\u70b9\uff0c\u544b\u55b9\u66ff\u5c3c\u7ec4\u60a3\u8005\u6570\u636e\u5747\u663e\u8457\u4f18\u4e8e\u5b89\u6170\u5242\u7ec4\uff0c\u5dee\u5f02\u5747\u6709\u7edf\u8ba1\u5b66\u610f\u4e49(\u4e3b\u8981\u7ec8\u70b9\u4e2d\u4f4d\u603b\u4f53\u751f\u5b58\u65f6\u95f49.30\u4e2a\u6708\u6bd46.57\u4e2a\u6708\uff0cP<0.001\uff1a\u6b21\u8981\u7ec8\u70b9\u65e0\u8fdb\u5c55\u751f\u5b58\u65f6\u95f43.71\u4e2a\u6708\u6bd41.84\u4e2a\u6708\uff0cP<0.001\uff1b\u6b21\u8981\u7ec8\u70b9\u5ba2\u89c2\u53cd\u5e94\u73874.7\uff05\u6bd40\uff0cP=0.012\uff1b\u6b21\u8981\u7ec8\u70b9\u75be\u75c5\u63a7\u5236\u738762.2\uff05\u6bd412.3\uff05\uff0cP<0.001)\uff0c\u4e14\u524d\u8005\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e35\uff05(\u98ce\u9669\u6bd4\u4e3a0.65)\u3002\u4e14\u544b\u55b9\u66ff\u5c3c\u5b89\u5168\u6027\u826f\u597d\uff0c\u4e0d\u826f\u53cd\u5e94\u53ef\u63a7\uff0c\u672a\u89c1\u4e25\u91cd\u975e\u9884\u671f\u5b89\u5168\u4fe1\u53f7\u3002\u56e0\u6b64\uff0c\u544b\u55b9\u66ff\u5c3c\u6216\u5c06\u6210\u4e3a\u665a\u671f\u7ed3\u76f4\u80a0\u764c\u4e09\u7ebf\u6cbb\u7597\u6807\u51c6\u7528\u836f\u4e4b\u4e00[44]<\/span><\/sup>\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u636e\u544b\u55b9\u66ff\u5c3c\u4e09\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u663e\u793a\uff0c\u8be5\u836f\u53ef\u964d\u4f4e\u60a3\u800535\uff05\u7684\u6b7b\u4ea1\u98ce\u9669\uff0c\u5e76\u53ef\u964d\u4f4e\u60a3\u800574\uff05\u7684\u75be\u75c5\u8fdb\u5c55\u98ce\u9669[45]<\/span><\/sup>\u3002\u7231\u4f18\u7279\u00ae<\/span><\/sup>\uff08\u544b\u55b9\u66ff\u5c3c\uff09\u4e3a\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7597\u9014\u5f84\u3002<\/span><\/p>\n

 <\/span><\/p>\n

\u53c2\u8003\u6587\u732e<\/span><\/p>\n

1.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PB0450.html(accessed September 2018).<\/span><\/p>\n

2.FDA\u5b98\u7f51\uff1ahttps:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm622044.htm(accessed September 2018).<\/span><\/p>\n

3.RegeneronPharmaceuticals\u5b98\u7f51\uff1ahttps:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/fda-approves-libtayor-cemiplimab-rwlc-first-and-only-treatment(accessed September 2018).<\/span><\/p>\n

4.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PB0272.html(accessed September 2018).<\/span><\/p>\n

5.\u65b0\u6d6a\u533b\u836f\u65b0\u95fb\uff1ahttp:\/\/med.sina.com\/article_detail_103_2_43730.html (accessed September2018).<\/span><\/p>\n

6.Lilly \u5b98\u7f51\uff1ahttps:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval(accessed September 2018).<\/span><\/p>\n

7.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PN0726.html(accessed September 2018).<\/span><\/p>\n

8.\u9648\u00b7\u675c\u514b\u68ee\u7d22\u65af\u00b7\u6cf0\u65af\u52d2\u9a6c\u4e01\u00b7\u683c\u5229\u592b. \u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684\u65b9\u6cd5, CN103958681A.<\/span><\/p>\n

9.\u4e2d\u6587\u7248\u764c\u75c7\u7efc\u5408\u4fe1\u606f\u5e93\uff1ahttp:\/\/pdq.cicams.ac.cn\/PDQ\/DATA\/CDR62932_zh_page1.html.(accessed September 2018)<\/span><\/p>\n

10.Lovly CM, Horn L. Molecular profiling of lungcancer. My Cancer Genome; 2016. Availableat:https:\/\/www.mycancergenome.org\/content\/disease\/lung-cancer\/. (accessedSeptember 2018)<\/span><\/p>\n

11.Pao W, Miller VA. Epidermal growth factor receptormutations, small-molecule kinase inhibitors, and non-small-cell lung cancer:current knowledge and future directions. J Clin Onc. 2005; 23:2556-2568.<\/span><\/p>\n

12.Pfizer\u5b98\u7f51\uff1ahttps:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer(accessed September 2018). <\/span><\/p>\n

13.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PN0858.html(accessed September 2018).<\/span><\/p>\n

14.\u4e2d\u534e\u533b\u5b66\u4f1a\u8840\u6db2\u5b66\u5206\u4f1a\u3001\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u8840\u6db2\u80bf\u7624\u4e13\u4e1a\u59d4\u5458\u4f1a\uff0c\u4e2d\u56fd\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\u7684\u8bca\u65ad\u4e0e\u6cbb\u7597\u6307\u5357\uff082015\u5e74\u7248\uff09\uff0c\u4e2d\u534e\u8840\u6db2\u5b66\u6742\u5fd72015\u5e7410\u6708\u7b2c36\u5377\u7b2c10\u671f\uff0c809-813.<\/span><\/p>\n

15.NCCN guidelines for patients: chronic lymphocyticleukemia 2018.<\/span><\/p>\n

16.\u5218\u6811\u6885, \u674e\u8389\u5a1f, \u5f20\u8fde\u751f. \u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\u514d\u75ab\u6cbb\u7597\u65b0\u8fdb\u5c55[J]. \u4e2d\u56fd\u80bf\u7624\u751f\u7269\u6cbb\u7597\u6742\u5fd7, 2016, 23(4): 566-570.<\/span><\/p>\n

17.FDADatabase.<\/span><\/p>\n

https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf(accessed September 2018).<\/span><\/p>\n

18.Drugbank https:\/\/www.drugbank.ca\/drugs\/DB11952  (accessed September 2018).<\/span><\/p>\n

19.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PB0583.html(accessed September 2018).<\/span><\/p>\n

20.\u6c6a\u6676\u6676, \u6f58\u6c38\u60e0. CGRP \u4e0e\u504f\u5934\u75db\u4f34\u53d1\u7126\u8651\u6291\u90c1\u7684\u5173\u7cfb.\u300a\u8111\u4e0e\u795e\u7ecf\u75be\u75c5\u6742\u5fd7\u300b, 2017\u5e74\u7b2c4\u671f252-256.<\/span><\/p>\n

21.FDA Database. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761089s000lbl.pdf(accessed September 2018).<\/span><\/p>\n

22.\u65b0\u6d6a\u533b\u836f\u65b0\u95fb\uff1ahttp:\/\/med.sina.com\/article_detail_103_2_52798.html(accessed September 2018).<\/span><\/p>\n

23.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PB0217.html(accessed September 2018).<\/span><\/p>\n

24.A+\u533b\u5b66\u767e\u79d1\uff1ahttp:\/\/www.a-hospital.com\/w\/%E6%AF%9B%E7%BB%86%E8%83%9E%E7%99%BD%E8%A1%80%E7%97%85.<\/span><\/p>\n

25.AstraZeneca \u5b98\u7f51\uff1ahttps:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia.html(accessed September 2018).<\/span><\/p>\n

26.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PN1278.html(accessed September 2018).<\/span><\/p>\n

27.\u5f90\u5f00\u6797\uff0c\u66f9\u6c5f. \u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u57fa\u56e0\u7a81\u53d8\u7814\u7a76\u73b0\u72b6\u53ca\u5c55\u671b\uff0c\u300a\u56fd\u9645\u8f93\u8840\u53ca\u8840\u6db2\u5b66\u6742\u5fd7\u300b\uff0c2016\u5e74\u7b2c1\u671f1-3.<\/span><\/p>\n

28.\u5362\u6768\uff0c\u6155\u4fd0\u541b\uff0c\u5f20\u65d7\uff0c\u5b59\u5065\uff0c\u674e\u4f1f\u5e73\uff0c\u738b\u6653\u6ce2. \u8001\u5e74\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u7279\u70b9\u53ca\u5176\u8bca\u6cbb\u8fdb\u5c55\uff0c\u300a\u5b9e\u7528\u8001\u5e74\u533b\u5b66\u300b\uff0c2014\u5e74\u7b2c2\u671f162-165.<\/span><\/p>\n

29.HematologyTimes\uff1ahttps:\/\/www.hematologytimes.com\/section\/leukemias\/article\/flt3-inhibitor-approved-for-rel-ref-aml-in-japan\/(accessed September 2018).<\/span><\/p>\n

30.\u65b0\u6d6a\u533b\u836f\u65b0\u95fb\uff1ahttp:\/\/med.sina.com\/article_detail_103_2_30351.html(accessed September 2018).<\/span><\/p>\n

31.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PC932.html(accessed September 2018).<\/span><\/p>\n

32.\u767e\u79d1\u540d\u533b\u7f51\uff1ahttps:\/\/www.baikemy.com\/disease\/detail\/5046\/1 (accessedSeptember 2018).<\/span><\/p>\n

33.\uff1ahttp:\/\/www.biodiscover.com\/news\/industry\/535605.html (accessed September 2018).<\/span><\/p>\n

34.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PN0964.html(accessed September 2018).<\/span><\/p>\n

35.\u9ec4\u9e92\u9716, \u987e\u660a\u715c, \u4e25\u52c7, \u9648\u83ca\u7965. \u95f4\u53d8\u6027\u6dcb\u5df4\u7624\u6fc0\u9176\u57fa\u56e0\u9633\u6027\u7684\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u8111\u8f6c\u79fb\u7684\u9776\u5411\u6cbb\u7597\u8fdb\u5c55. \u300a\u4e2d\u56fd\u80bf\u7624\u751f\u7269\u6cbb\u7597\u6742\u5fd7\u300b, 2018\u5e74\u7b2c4\u671f431-436.<\/span><\/p>\n

36.\u641c\u72d0\u7f51\uff1ahttps:\/\/www.sohu.com\/a\/222499651_464396 (accessedSeptember 2018).<\/span><\/p>\n

37.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PN2529.html(accessed September 2018).<\/span><\/p>\n

38.\u9752\u5149\u773c.\u300a\u533b\u5b66\u6587\u9009\u300b, 1991, \u7b2c5\u671f, 59-60.<\/span><\/p>\n

39.\u674e\u5efa\u519b, \u738b\u723d, \u5f90\u4eae. \u9ad8\u773c\u538b\u75c7.\u300a\u56fd\u5916\u533b\u5b66\uff1a\u773c\u79d1\u5b66\u5206\u518c\u300b, 2005, 29(1), 66-70.<\/span><\/p>\n

40.\u6570\u636e\uff1ahttps:\/\/data.pharmacodia.com\/web\/basic\/basic_detail_PN0857.html(accessed September 2018).<\/span><\/p>\n

41.\u5f90\u96f7\u9e23. \u7ed3\u80a0\u76f4\u80a0\u764c\u7684\u5185\u955c\u5fae\u521b\u6cbb\u7597.\u300a\u5916\u79d1\u7406\u8bba\u4e0e\u5b9e\u8df5\u300b, 2010, 15(4), 346-347.<\/span><\/p>\n

42.Geng, Fang; Wang, Zheng; Yin, Hang; Yu, Junxian;Cao, Bangwei.CancerBiotherapy & Radiopharmaceuticals; New Rochelle 2017, 32(5), 149-160.<\/span><\/p>\n

43.\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\u5b98\u7f51\uff1ahttp:\/\/www.nmp.gov.cn\/gzxgz\/zdxy\/201809\/t20180912_5978.htm.(accessed September 2018)<\/span><\/p>\n

44.\u6731\u5fb7\u7965\uff0c\u8bb8\u5251\u6c11.2017\u5e74\u4e2d\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\u5e74\u4f1a\u7ed3\u76f4\u80a0\u764c\u7814\u7a76\u8fdb\u5c55\u89e3\u6790.\u300a\u4e2d\u534e\u6d88\u5316\u5916\u79d1\u6742\u5fd7\u300b, 2017, 16(11), 1101-1104.<\/span><\/p>\n

45.\u4e2d\u56fd\u79d1\u6280\u7f51\uff1ahttp:\/\/www.stdaily.com\/index\/kejixinwen\/2018-09\/07\/content_707098.shtml(accessed September 2018).<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
\n
\n
\u4f5c\u8005\u7b80\u4ecb<\/section>\n
<\/section>\n<\/section>\n
\n

2011\u5e74\u5357\u5f00\u5927\u5b66\u5316\u5b66\u5b66\u9662\u7855\u58eb\u6bd5\u4e1a\u3002\u73b0\u5728\u5728\u7ecf\u7eac\u4fe1\u606f\u79d1\u6280\uff08\u5317\u4eac\uff09\u6709\u9650\u516c\u53f8\u4ece\u4e8b\u6570\u636e\u5e93\u4fe1\u606f\u7684\u6536\u96c6\u548c\u7f16\u5199\u5de5\u4f5c\uff0c\u7814\u7a76\u751f\u671f\u95f4\u4e3b\u8981\u4ece\u4e8bAHAS\u6291\u5236\u5242\u7684\u5316\u5b66\u5408\u6210\u53ca\u4f53\u5916\u6d3b\u6027\u6d4b\u8bd5\u30022011-2014\u5165\u804c\u4fdd\u8bfa\u79d1\u6280(\u5317\u4eac)\u6709\u9650\u516c\u53f8\u4ece\u4e8b\u5c0f\u5206\u5b50\u5316\u5408\u7269\u7684\u5408\u6210\uff0c2014-2015\u5728\u6c47\u5eb7\u535a\u6e90\u4ece\u4e8b\u7cd6\u5c3f\u75c5\u836f\u7269\u7684\u5de5\u827a\u8def\u7ebf\u4f18\u5316\u53ca\u4e2d\u8bd5\u3002\u5728\u5de5\u4f5c\u671f\u95f4\u8fd8\u66fe\u8d1f\u8d23\u5c0f\u5206\u5b50\u6291\u5236\u5242\u7684\u9500\u552e\u4e0e\u91c7\u8d2d\u5de5\u4f5c\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

2018\u5e749\u6708\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u5171\u6279\u51c62\u4e2a\u65b0\u5206\u5b50\u5b9e\u4f53\uff08NME\uff09\u836f\u7269\uff0c\u5206\u522b\u662f\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684D […]<\/p>\n","protected":false},"author":1,"featured_media":70202,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/70201"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=70201"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/70201\/revisions"}],"predecessor-version":[{"id":70226,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/70201\/revisions\/70226"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/70202"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=70201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=70201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=70201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}